 
 Clinical Trial Protocol: NAV3 -35 
Study Title:  Development of a Normative Database for Rheumatoid Arthritis 
(RA) Imaging with Tc  99m Tilmanocept  
Study Number:  NAV3 -35 
Study Phase:  Phase 2b  
Product Name:  Technetium Tc 99m tilmanocept  
IND Number:  132943  
Investigators:  Multicenter  
Sponsor:  Navidea Biopharmaceuticals, Inc.  
4995 Bradenton Ave., Suite 240 
Dublin, OH 43017 
Sponsor 
Contact:  Rachael Hershey , MS, CCR P 
Clinical Research Project Manager  
(614) 822-2329 
Medical 
Monitor:  Michael Blue, MD, FACEP  
Senior Medical Director  
(614) 571-4313 
 
 Date  
Original Protocol:  17 March  2021 
           
Confidentiality Statement 
This document and its contents are the property of and confidential to Navidea 
Biopharmaceuticals. Any unauthorized copying or use of this document is prohibited.   
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 2 of 74 
 SYNOPSIS 
Study Title:  
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging with Tc 
99m Tilmanocept   
Study Number:  
NAV3 -35 
Study Phase:  Phase 2b  
Primary Objective (s):  
‚Ä¢ To establish mean and variance of  joint- specific Tilmanocept Uptake Value 
(TUV joint) in healthy controls ( HCs) age -matched to RA population.  
‚Ä¢ To assess the feasibility of detecting Tc 99m tilmanocept anatomic localization 
using s ingle photon emission computed tomography/computed tomography 
(SPECT/CT) imaging of hands and wrists in  HCs and subjects with active RA .   
Secondary Objective(s):  
‚Ä¢ To quantitate Tc 99m tilmanocept anatomic localization based on  SPECT/CT 
imaging of hands and wrists in  HCs and joints with RA-involved inflammation. 
Safety Objective:  
‚Ä¢ To evaluate safety through the examination of adverse event (AE) incidence and changes over time in laboratory tests, vital signs, and physical examination 
findings.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 3 of 74 
 Inclusion Criteria:   
ALL SUBJECTS  
1. The subject has provided written informed consent with HIPAA (Health 
Information Portability and Accountability Act) authorization before the initiation of any study- related procedures.  
2. The subject has agreed to not engage in any diet, lifestyle, or medication changes until study completion.  
 HEALTHY CONTROL SUBJECTS  
3. The subject is 30 years of age or greater at the time of consent.  
4. The subject is deemed to be clinically free of any inflammatory disease (s), auto-
immune disease(s), or arthropathies and has not experienced joint pain for at least 28 days prior to the consent date. 
5. The subject is not currently on anti-inflammatory drugs (including non- steroidal 
anti-inflammatory drugs [NSAIDs]) and has not taken any anti- inflammatories 
for at least 28 days prior to the consent date.  
6. For all ongoing concomitant medications, the subject has maintained a stable dose for at least 28 days prior to the consent date. 
 RA SUBJECTS  
3. The subject is at least 18 years of age and was ‚â• 18 years of age at the time of RA diagnosis. 
4. The subject has moderate to severe RA as determined by the 2010 American College of Rheumatology/European League Against Rhe umatism 
(ACR/EULAR ) Classification Criteria  (score of ‚â• 6/10). 
5. The subject has a 28- joint disease activity score ( DAS28 ) of ‚â• 3.2 (includes the 
Erythrocyte Sedimentation Rate [ESR] test and Visual Analog Scal e [VAS]). 
6. Subjects receiving traditional DMARDs must have been on therapy for ‚â• 90 days and at a stable dose for ‚â• 30 days prior to the imaging visit (Day 0). 
7. If the subject is receiving b DMARD or janus kinase ( JAK) inhibitor therapy, 
they have been at a stable dose > 60 days  prior to the imaging visit (Day  0).  
8. If the subject is receiving NSAIDs or
 oral corticosteroids, the dose has been 
stable for ‚â•  28 days prior to the imaging visit (Day 0). The corticosteroid dose 
must be ‚â§ 10 mg/day of prednisone or an equivalent steroid dose. 
 
Exclusion Criteria:  1. The subject is pregnant or lactating.  
2. The subject  size or weight is not compatible with imaging per the investigator . 
3. The subject is currently receiving radiation therapy or chemotherapy or has received radiation therapy or chemotherapy in the past six months. 
4. The subject has had a finger, hand, and/or wrist amputation or hand or wrist joint arthroplasty.  
5. The subject has renal insufficiency as demonstrated by a glomerular filtration rate  
of < 60 mL/min.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 4 of 74 
 6. The subject has hepatic insuffi ciency as demonstrated by ALT (alanine 
aminotransferase [SGPT]) or AST  (aspartate aminotransferase [SGOT])  greater 
than 2 times the upper limit of normal.  
7. The subject has any severe, acute, or chronic medical  conditions and/or psychiatric 
conditions and/or laboratory abnormalities that would impart, in the judgment of 
the investigator, excess risk associated with study participation or study drug administration  that would deem the subject inappropriate for study participation or 
compromise the safety of the subject or the quality of the data. 
8. The subject has any unstable medical illnesses , including hepatic, renal, 
gastroenterologic, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. 
9. The subject has a known allergy to or has had an adverse reaction to dextran exposure. 
10. The subject has received an investigational product within 30 days prior to Tc 99m tilmanocept administration  (Day 0). 
11. The subject has received intra- articular corticosteroid inje ctions ‚â§ 8 weeks prior to 
Tc 99m tilmanocept administration  (Day 0) . 
12. The subject has received any radiopharmaceutical within 7 days or 10 half- lives 
prior to Tc 99m tilmanocept administration  (Day 0) . 
13. Healthy Controls only: The subject has a positive rheumatoid factor and  an 
elevated ESR or CRP.  
 Study Design:  
This is a prospective, open- label, multicenter, single -dose study designed to develop a 
normative database of TUV
joint in HCs and to assess the feasibility of qualitative and 
quantitative SPECT/CT assessments in HCs and subjects with active RA  following Tc 
99m tilmanocept administration . 
Tilmanocept Uptake Value ( TUV ) is a quantitative imaging metric used to characterize 
Tc 99m tilmanocept uptake on planar imaging. Results from prior Phase 1 and 2 studies  have demonstrated that TUV is a sensitive and specific predictor of visually 
interrogated Tc 99m tilmanocept localization in joint regions with presumed inflammatory macrophage activity. A per -joint TUV (TUV
joint) relati ve ratio will be 
calculated for the each of the 22 DAS -28 joints located in the hands and wrists. A 
subject -level global TUV (TUV global) assessed across the 22 joints will be used as an 
indication of overall disease burden. TUV metrics are further describe d in the NAV3 -
35 Statistical Analysis Plan.  
This study is stratified into 2 arms . Arm 1 is compris ed of 120 HCs , and Arm 2 is 
comprised of 5 HCs and 10 clinically diagnosed RA subjects on stable treatment.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 5 of 74 
 Rationale for Sample Size:  
The study will enroll up to 135 evaluable subjects in Arms 1 and 2 allocated below, 
imaged at up to 8 study centers. Arm 1 will have N = 120 evaluable HC subjects, Arm 2 
will have N = 15 (5 HCs and 10 RA) evaluable subjects. A subject is considered 
evaluable if he/she me ets the criteria for the analysis population and has the data 
necessary for computing the primary endpoint.  
The sample size for Arm 1 was determined to provide acceptable precision for the 
estimated 5 and 95 percentiles. These percentiles will be estimated  with 95% 
nonparametric confidence intervals. Although the standard error formula for quantile 
estimators is known and quantile estimators obey a central limit theorem, relying on the asymptotic Normal distribution seems imprudent.  
The sample will be stratified 3:1, females  males to reflect RA incidence in the United 
States. The sex -specific samples will be further stratified by age to reflect the Census 
estimated US population in 2019. The target sample sizes are given below. 
Age Range  Male  Female  Total  
30 to 39 years  8 23 31 
40 to 49 years  7 21 28 
50 to 59 years  8 22 30 
60 to 69 years  7 21 28 
70 years and oldera 6 21 27 
Total  36 108 144 
a An effort will be made to target enrollment in this group to include 2 men and 8 women 80 years old and 
over.  
The existing data for HC subjects was used in a bootstrap procedure to evaluate the width of 95% confidence intervals for the 95 percentiles for various sample sizes. The sponsor 
has decided for its business purposes that knowing the percentile to within 0.05 of its 
true value is sufficient. A sample of size N = 144 HC results (this includes the subjects from Arm 1 of NAV3 -31) in 95% confidence inter vals with half -widths less than 0.05. 
The sample size for Arm 2 was determined to be sufficient for the business purposes of the sponsor. The sample size for Arm 2 will be 5 HCs and 10 RA subjects.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 6 of 74 
 Efficacy  Assessments:  
Primary Endpoint(s) 
ARM 1  
‚Ä¢ The normal limits of TUV joint (on a per joint basis) in HC subjects, which are 
defined as the 5 and 95 percentiles of TUVjoint of bilateral  joints (i.e., bilateral 
wrists, m etacarpophalangeal joint [MCPs], p roximal interphalangeal [PIPs]). 
The normal range will be determined separately for each of the three blinded 
readers.  
 ARM 2  
‚Ä¢ The qualitative evaluations of SPECT/CT in detecting localization within synovial spaces of the bilateral hands and wrists in HCs and RA subjects. 
 
Secondary Endpoints 
ARM 1  
‚Ä¢ Applicability of the Normal (Gaussian) distribution to TUV joint data.  
 
 ARM 2  
‚Ä¢ Quantitative evaluations of Tc 99m tilmanocept localization from SPECT/CT 
within synovial spaces of the bilateral hands and wrists in HCs and RA 
subjects.  
‚Ä¢ Normative joint- specific standardized uptake value ( SUV). 
 
‚Ä¢ Predictive value of planar scans for SPECT/CT scans.  
 
Statistical Methods:  
Primary Endpoint Arm 1  
The distribution of TUV joint in HC subjects will be summarized with descriptive 
statistics: mean, standard deviation, n, minimum, maximum, and median per reader, 
joint, and view. The 5 and 95 percentiles will be estimated with quanti le regression fitting 
an intercept as a fixed term. The lower and upper limits of normal TUV joint will be 
determined using non- parametric confidence intervals and kernel density -based 
confidence intervals.  
Primary Endpoint Arm 2  
Localization of tilmanocept in the hands and wrists will be summarized with frequency 
counts and percentages by reader and joint. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 7 of 74 
 Secondary Endpoint Arm 1  
Normal quantile plots will be provided per joint and reader, along with the p- value for 
the Shapiro- Wilk test of Normality.  
Secondary Endpoint s Arm 2  
SUV will be calculated and summarized on both a per- joint and a total of all joints with 
summary statistics: mean, standard deviation, n, minimum, maximum, and median. 
The predictive value of planar scans for SPECT/CT qualitative fin dings will be 
summarized per joint and reader with a crosstabulation and the uncertainty coefficients 
for row | column, column | row, and symmetric. The planar result will be deemed 
‚Äúpositive‚Äù (i.e., inflamed) if TUV joint > 95 percentile of the reader resu lts for the same 
joint in Arm 1. Otherwise, the planar result will be deemed ‚Äúnegative‚Äù.  
Additional statistical methods are described in Section 9.5 and in the NAV3-35 
Statistical A
nalysis Plan.  
Date of Original Approved Protocol:  17 March  2021 
 
  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 8 of 74 
 TABLE OF CONTENTS  
SYNOPSIS  .................................................................................................................................2  
Primary Endpoint Arm 1 ..........................................................................................6  
Primary Endpoint Arm 2 ..........................................................................................6  
Secondary Endpoint Arm 1 ......................................................................................7  
Secondary Endpoints Arm 2.....................................................................................7  
LIST OF IN -TEXT TABLES  ..................................................................................................12  
LIST OF IN -TEXT FIGURES .................................................................................................13  
LIST OF APPENDICES  ..........................................................................................................14  
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ..........................................15  
1 INTRODUCTION  ...........................................................................................................18  
1.1 Background ............................................................................................................18  
1.2 Previous Nonclinical Research and Clinical Trial Experience in Tc 99m 
Tilmanocept  ...........................................................................................................23  
1.2.1  Nonclinical Evaluations ‚ÄìSubcutaneous Administration.............................23  
1.2.2  Nonclinical Evaluations ‚Äì IV Administration ..............................................23  
1.2.3  Clinical Pharmacokinetics (IV) ....................................................................25  
1.2.4  Clinical Efficacy  ..........................................................................................26  
1.2.4.1  NAV3 -23 (SC) ...................................................................................26  
1.2.4.2  NAV3 -21 (IV) ....................................................................................27  
1.2.4.3  NAV3 -31 (IV) ....................................................................................27  
1.2.5  Clinical Safety  ..............................................................................................28  
1.2.5.1  NAV3 -23 (SC) ...................................................................................28  
1.2.5.2  NAV3 -21 (IV) ....................................................................................28  
1.2.5.3  NAV3 -31 (IV) ....................................................................................28  
2 STUDY OBJECTIVES  ....................................................................................................29  
2.1 Primary Objective(s)  ..............................................................................................29  
2.2 Secondary Objective(s)  ..........................................................................................29  
2.3 Safety Objective(s) .................................................................................................29  
3 INVESTIGATIONAL PLAN  ..........................................................................................30  
3.1 Overall Study Design and Plan ..............................................................................30  
3.1.1  Arm 1: No Inflammatory and/or Joint Disease (HC Subjects)  ....................30  
3.1.1.1  Description of Patient Population ......................................................30  
3.1.1.2  Overview  of Study Procedures ..........................................................30  
3.1.1.3  Justification for Population ................................................................30  
3.1.2  Arm 2: HCs and RA Subjects on Stable Anti- Rheumatic Therapy  .............31  
3.1.2.1  Description of Patient Population ......................................................31  
3.1.2.2  Overview  of Study Procedures ..........................................................31  
3.1.2.3  Justification for Population ................................................................31  
3.2 Protocol Adherence ................................................................................................32  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 9 of 74 
 3.3 Study Duration(s) ...................................................................................................32  
4 STUDY POPULATION  ..................................................................................................33  
4.1 Study Arms ............................................................................................................33  
4.2 Eligibility  ...............................................................................................................33  
4.2.1  Inclusion Criteria  .........................................................................................33  
4.2.2  Exclusion Criteria  ........................................................................................34  
4.3 Recruitment  ............................................................................................................35  
4.4 Withdrawal  .............................................................................................................35  
4.5 Replacement  ...........................................................................................................36  
4.6 Screen Failures  .......................................................................................................36  
4.7 Subject Identification  .............................................................................................36  
5 INVESTIGATIONAL PRODUCT  ..................................................................................37  
5.1 Description of Investigational Project ...................................................................37  
5.2 Investigational Product Dosage and Administration .............................................37  
5.3 Timing and Frequency of Drug Administration ....................................................38  
5.4 Packaging and Labeling .........................................................................................38  
5.5 Drug Logistics and Investigational Product Accountability ..................................38  
6 THERAPIES OTHER THAN INVESTIGATIONAL PRODUCT  .................................39  
6.1 Prior and Concomitant Therapies ..........................................................................39  
6.2 Post-Study Therapy ................................................................................................39  
7 STUDY PROCEDURES  .................................................................................................40  
7.1 Schedule of Evaluations .........................................................................................40  
7.1.1  Arm 1  ...........................................................................................................40  
7.1.2  Arm 2  ...........................................................................................................42  
8 PROCEDURES AND VARIABLES  ..............................................................................44  
8.1 Population Characteristics  .....................................................................................44  
8.1.1  Demographics and Other Baseline Characteristics  ......................................44  
8.1.2  Medical, Rheumatological, and Surgical History ........................................44  
8.1.3  Prior and Concomitant Medication ..............................................................44  
8.2 Tc 99m Tilmanocept Administration  .....................................................................44  
8.3 Rheumatological Assessments  ...............................................................................44  
8.3.1  2010 ACR/EULAR Class ification Criteria  ..................................................44  
8.3.2  DAS28 ..........................................................................................................45  
8.3.3  Other  ............................................................................................................45  
8.3.3.1  28-joint Count (SJC and TJC)............................................................45  
8.3.3.2  Patient Asse ssment of Pain (VAS) ....................................................45  
8.3.3.3  Acute- phase Reactant .........................................................................45  
8.4 Imaging ..................................................................................................................46  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 10 of 74 
 8.4.1  Image Acquisition  ........................................................................................46  
8.4.1.1  Planar Scintigraphy ............................................................................46  
8.4.1.2  SPECT/CT  .........................................................................................46  
8.4.2  Tilmanocept Uptake Value (TUV)  ..............................................................46  
8.5 Adverse Events  ......................................................................................................46  
8.5.1  Definition of Adverse Event ........................................................................46  
8.5.2  Categories for Adverse Event Assessment  ..................................................47  
8.5.3  Assessments and Documentation of Adverse Events ..................................48  
8.5.4  Expected Adverse Events  ............................................................................49  
8.5.5  Serious Adverse Events ...............................................................................50  
8.6 Physical Examination .............................................................................................51  
8.7 Vital Signs  ..............................................................................................................52  
8.8 Clinical Laboratory Parameters  .............................................................................52  
9 STATISTICAL METHODS  ............................................................................................54  
9.1 Randomization Methods ........................................................................................54  
9.2 Safety Variables  .....................................................................................................54  
9.3 Efficacy Variables  ..................................................................................................54  
9.4 Sample Size Justification  .......................................................................................55  
9.5 Statistical Analyses  ................................................................................................56  
9.5.1  Analysis Populations ....................................................................................56  
9.5.2  Analysis of Baseline and Demographic Characteristics  ..............................56  
9.5.3  Analysis of Efficacy Variables  ....................................................................57  
9.5.3.1  Primary Endpoint Arm 1 ....................................................................57  
9.5.3.2  Primary Endpoint Arm 2 ....................................................................57  
9.5.3.3  Secondary Endpoint Arm 1 ................................................................57  
9.5.3.4  Secondary Endpoints Arm 2 ..............................................................57  
9.5.4  Analysis of Safety Variables ........................................................................57  
9.5.5  Handling of Missing Values ........................................................................58  
9.5.6  Interim Analyses  ..........................................................................................58  
10 DATA HANDLING AND QUALITY ASSURANCE  ...................................................59  
10.1  Data Recording  ......................................................................................................59  
10.1.1  CRF Design  ..................................................................................................59  
10.2  Monitoring .............................................................................................................59  
10.3  Data Processing  ......................................................................................................59  
10.4  Auditing .................................................................................................................59  
10.5  Archiving ...............................................................................................................60  
10.6  Premature Termination of the Study ......................................................................60  
10.6.1  Termination by the Sponsor .........................................................................60  
10.6.2  Termination by the Investigator ...................................................................60  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 11 of 74 
 10.6.3  Study as a Whole .........................................................................................61  
10.6.4  Center  ...........................................................................................................61  
10.6.5  Study Participant ..........................................................................................61  
11 ETHICAL AND LEGAL ASPECTS ...............................................................................62  
11.1  Ethical and Legal Conduct of the Study ................................................................62  
11.2  Subject Information and Consent...........................................................................62  
11.3  Financing/Financial Disclosure  .............................................................................63  
11.4  Publication Policy  ..................................................................................................63  
11.5  Subject Injury .........................................................................................................63  
12 REFERENCES  ................................................................................................................64  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 12 of 74 
 LIST OF IN -TEXT TABLES  
Table 1  Preclinical Tests  .........................................................................................24  
Table 2  Whole Blood PK Parameter Summaries by Group....................................25  
Table 3  Urine PK Parameter Summaries by Group  ................................................26  
Table 4  Study Arms ................................................................................................30  
Table 5  Inclusion Criteria Treatment Windows for Recent or Concomitant RA-
specific Treatments  ....................................................................................31  
Table 6  Study Arms ................................................................................................33  
Table 7  Clinical Laboratory Parameters  .................................................................52  
Table 8  Approximate Amount of Blood Drawn .....................................................53  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 13 of 74 
 LIST OF IN -TEXT FIGURES  
Figure 1  Tc 99m tilmanocept and the Mannose Receptor........................................37  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 14 of 74 
 LIST OF APPENDICES  
Appendix 1  Schedule of Events .....................................................................................69  
Appendix 2  2010 ACR/EULAR Criteria .......................................................................70  
Appendix 3  DAS28 Scoring ..........................................................................................72  
Appendix 4  Sponsor Signatures.....................................................................................73  
Appendix 5  Investigator‚Äôs Signature .............................................................................74  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 15 of 74 
 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
ACPA  Anti-Citrullinated Peptide Antibody  
ACR  American College of Rheumatology  
ACR 12/24w  American College of Rheumatology response criteria at 12 ¬± 1 weeks / 
24 ¬± 1 weeks of newly initiated bDMARD therapy and baseline 
ACR20/50/70  American College of Rheumatology response criteria  
ACR/EULAR  American College of Rheumatology/European League Against 
Rheumatism 
AE Adverse event  
ALT  Alanine A minotransferase  
AST  Aspartate Aminotransferase  
AUC  Area Under the Curve  
bDMARD  Biological disease -modifying antirheumatic drug  
BMI  Body Mass Index  
CD206  Mannose -binding receptor (Ca2+ -binding lectin)  
CDAI  Clinical disease activity index  
CFB  Change from baseline  
CRF  Case Report Form  
CRO  Contract Research Organization  
CRP  C-Reactive Protein  
CV Coefficient of variation  
DAS28  Disease activity score -28 for RA describing the severity of RA using 
clinical and laboratory data. 
DMARD  Disease -modifying antirheumatic drug  
DTPA  Diethylenetriaminepentaacetic A cid 
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form 
ESR Erythrocyte Sedimentation Rate  
GCP  Good Clinical Practice  
HC Healthy control  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 16 of 74 
 ICF Informed Consent F orm 
ICH International Conference on Harmonization  
IHC Immunohistochemistry  
ITD Intent to Diagnose  
IND Investigational New Drug  
IRB Institutional Review Board  
IV Intravenous  
MCP  Metacarpophalangeal joint  
NSAID  Non-steroidal anti-inflammatory drug  
PIP Proximal Interphalangeal  
PK Pharmacokinetics  
PP Per Protocol  
QT Interval from the Q wave to the end of the T wave  
QTc Corrected QT Interval  
RA Rheumatoid arthritis  
RF Rheumatoid Factor  
RMSD  Root mean square difference  
ROC  Receiver Operating Characteristic  
ROI Region of interest  
RR Reference region  
RSNA  Radiological Society of North America  
SAP Statistical Analysis Plan  
SJC Swollen joint count  
SC Sulfur Colloid  
SOC  System Organ Class  
SPECT  Single -Photon Emission Computerized Tomography  
SPECT/CT  Combined Single -Photon Emission Computerized Tomography and 
computed tomography 
SUV  Standardized Uptake Value  
TJC Tender joint count  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 17 of 74 
 TMF  Trial Master File  
TNF Œ± Tumor necrosis factor alpha  
TUV  Tilmanocept Uptake Value  
TUV global Global Tilmanocept Uptake Value  
TUV joint Joint -specific Tilmanocept Uptake Value  
UC Uncertainty Coefficient  
ULN  Upper limit of normal  
VAS  Visual Analog Scal e 
WB  Whole body  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 18 of 74 
 1 INTRODUCTION 
1.1 Background 
Worldwide, approximately 1 in 200 adults suffer from RA. In the US, 1.3 million adults are 
living with RA. Each year, about 130,000 Americans are newly diagnosed with RA. Persons 
with inadequately controlled RA have significantly shorter life expectancies and frequently become disabled, leading to reduced quality of life and severe adverse economic consequences  
[1-4]. 
It has been realized for many years that RA patients who are placed on DMARDs soon after they develop arthritis symptoms respond much more favorably to these therapies than do patients whose initiation of DMARD therapy is delayed [5]. Many more of thes e early RA 
patients placed on therapy achieve disease remission than is observed in RA patients who  do 
not initiate DMARD therapy until after they have been symptomatic for RA for 6 or more months. Furthermore, those early RA patients placed on timely therapy who do not achieve remission experience less severe disease [ 6-8]. Indeed , the early diagnosis of RA affords a 
‚Äúwindow of opportunity‚Äù for the greatest probability of effective RA therapy and the possibility of disease remission [ 9]. This window closes 3 to 6 months after patients become symptomatic 
with RA. The problem is that only a portion of patients first presenting with arthritis have RA and differentiating those patients who have RA from those who do not is challenging, leading frequently to delays in accurately identifying those patients with RA.  
The realization that early diagnosis of RA is critical for delivering the most effective RA 
treatment led to a collaboration between t he American College of Rheumatology and the 
European League Against Rheumatism (ACR/EULAR) that resulted in 2010 in the publication of new criteria for diagnosi ng RA [10]. The intent of the ACR/EULAR 2010 criteria was to 
improve the diagnosis of early RA. This intent was only partially realized. There have been numerous publications reporting the results of studies evaluating the diagnostic accuracy of the ACR/EULAR 2010 criteria for identifying early RA patients. In a meta -analysis of this  
literature [11], it was shown that the ACR/EULAR 2010 criteria has a 73% sensitivity and a 
74% specificity for correctly identifying early RA. If the ACR/EULAR 2010 criteria are used to decide who should receive DMARD therapy, this meta -analysis indicates that over a quarter 
of true early RA patients would not be provided with appropriate DMARD therapy during the critical window of opportunity for  an optimal response. Furthermore, a significant portion of 
arthritis patients who do not have RA would be prescribed DMARD therapies for which they would not receive benefit and would be exposed to possible adverse side effects of the drugs. Clearly there remains an unmet need for a more accurate means to identify early RA patients , 
to improve aggregate outcomes for early RA patients , and to reduce adverse drug effects and 
healthcare co sts associated with unproductive delivery of RA therapies to individuals who do 
not have RA.  
Basic research on the pathobiology of RA has revealed that the inflammation observed in RA 
is the consequence of a self -perpetuating pathological alteration in th e expression and 
downstream signaling of a network of cytokines  [12, 13]. Frequently, a t the center of this 
cytokine network is the overexpression of tumor necrosis factor alpha (TNFŒ±)  [14-17]. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 19 of 74 
 Recognition of the importance of disturbances in cytokine expression and especially that of 
TNFùõºùõº formed the underlying rationale for the development of many antibody based bi ologic 
therapies intended to block signaling by TNF ùõºùõº or one of the other various inflammatory 
cytokines involved in RA pathology [ 18-21] . Many of these cytokine -directed RA biologic 
therapies have been granted regulatory approval and are currently commercially available.  
While many RA patients have benefited from recent advances in RA therapies, problems and 
deficiencies remain. Among these problems and deficiencies are:  
‚Ä¢ A significant portion of RA patients do not respond to RA therapies or respond 
insufficiently to RA therapies to achieve therapeutic goals [ 22, 23] , 
‚Ä¢ All current RA therapies are associated with adverse effects, which can be common and/or severe [ 24],  
‚Ä¢ Many cu rrent RA therapies, especially the biologic therapies , are exceedingly 
expensive, placing an imposing burden on healthcare costs [ 25] and affordability [ 26], 
and 
‚Ä¢ Nearly all RA therapies lack an adequate defined diagnostic element that can facilitate  
choosing an individual patient‚Äôs therapeutic regimen  that provides the highest 
probability of an effective treatment response.  
 Quantitative assessment of CD206 positivity of inflamed synovia in RA patients is expected to remedy, at least partially, all 4 of these problems and deficiencies.  Tc 99m tilmanocept is a 
synthetic radiopharmaceutical imaging agent that was purposefully designed to be a high affinity ligand for CD206. CD206 is highly upregulated on phenotypically activated 
macrophages that contribute mechanistically to the underlying pathobiology of RA.  It has long 
been  recognized  that activated  macrophages  contribute significantly  to RA pathology
 [27-29]. 
Macrophages  are common  in inflamed  synovial tissues  when  patients  are first diagnosed with 
RA [30] and frequently become more  numerous as the disease progre sses. Activated  
macrophages  produce most of the TNFŒ±  that, in a significant proportion of cases,  drives and 
perpetuates  the inflammatory  cycle in RA [14]. In the synovial sublining of a joint affected  by 
RA, activated  macrophages  are frequently the dominant cell type [31-33] . Activated  
macrophages  significantly  contribute to the destruction  of bone and cartilage through their 
secretion  of proteases  [34, 35]. Furthermore,  the densities  of synovial membrane macrophages 
measured  before  treatment,  and especially  the densities  of sublining macrophages,  have been  
reported  to predict  future  joint damage [36-39] . Not surprisingly, activated synovial 
mac
rophage numbers ‚Äîbut not the numbers of other immune cell types ‚Äîcorrelate with 
radiographically determined joint destruction in RA [ 36, 37]. Thus, CD206 positivity of 
inflamed synovia in RA patients is expected to provide clinically significant prognostic information for RA patients . Another important finding is that activated macrophage numbers 
are reduced by effective RA therapy [ 38], but do not significantly change over the course of at 
least months if a patient w as given ineffective RA therapy  [40]. Also, importantly, reductions 
in activated synovial macrophages associated with effective RA therapy typically occur before treatment mediated changes  in the severity of clinical symptoms can be observed [41]. Thus, 
a change in activated synovial macrophage numbers is now recognized as a biomarker that provides an objective and early measure of responses to RA therapies [ 42, 43].  In fact, a 
change in activated synovial macrophage numbers is considered a more accurate measure of 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 20 of 74 
 treatment response than clinical assessments, which are highly subjective in nature and prone 
to observer error [ 42, 44, 45]. Therefore, there is a possibility that future clinical studies may 
show that quantitative assessment of CD206 positivity of inflamed synovia in RA patients could be used to monitor the efficacy of RA therapies, providing physicians and patients  with 
earlier and more objective criteria to abandon ineffective therapies and adopt alternative therapies that may be more effective.  
In recent years, synovial biopsy- enabled studies have greatly increased our understanding of 
the pathological processes occurring within the inflamed joints of RA patients [ 39].  An 
important finding of these studies has  been that the inflammatory cell compositions of RA 
inflamed joints can vary between patients [ 46, 47]. The biopsy specimens obtained from 
different RA patients can have different numbers and densities of macrophages and monocytes, lymphocytes and lymphocyte containing structures, and fibroblast -like synoviocytes [48]. 
These differences in cellular composition suggest that RA inflammation can be divided into 3 pathotypes, referred to as diffuse m yeloid, lympho-myeloid, and fibroid respectively [ 49, 50] . 
Myeloid pathotype variants have  the highest density of macrophages, whereas  the fibroid 
pathotype is largely devoid of both macrophages and lymphoid cells. These  pathotypes are not 
fully discreet with some overlap occurring. However, they  provide a strong basis for temporal 
or cytological compartmentalization in RA disease natural history.  
Current studies utilizing IHC analyses of synovial biopsies are insufficie nt to determine the 
distribution of the various pathotypes in RA patients but suggest that the diffuse myeloid and 
lympho- myeloid  pathotypes are about equally frequent in RA patients with the fibroid  
pathotype being less common. There is growing evidence t hat patients with different RA 
pathotypes respond differently to various therapies, holding out the possibility that determining the RA pathotype of an individual patient‚Äôs RA can direct choice of the most effective therapy for that patient (i.e. , personal ized RA therapy) [ 50]. This is an area of ongoing active 
investigation in RA therapy research [ 51-53] . However, already there is significant evidence 
indicating that patients with a myeloid -driven  RA pathotype and/or with high densities of 
macrophages in their inflamed synovium respond best to anti -TNFŒ± biologic therapy [50, 54], 
whereas patients wi th a f ibroid pathotype do not respond significantly to anti -TNFŒ± therapy. 
Although these results need to be confirmed and elaborated upon in further studies, they 
suggest that determination of the density of activated macrophages in the inflamed synovial membranes of patients with RA could facilitate identification of those RA patients who  would 
most benefit from anti- TNFŒ± therapy and/or those who would not receive benefit. Additional 
work in this field seeks to determine if similar associations between the efficacies of other treatments and synovial pathotypes can identify those treatme nts that are most effective in 
patients with lympho- myeloid and/or fibroid RA pathotypes. Such results, if attained, would 
provide a great benefit to RA patients by enabling personalized delivery of an optimal 
treatments to all RA patients.  
Previously generated results from clinical imaging studies conducted by Navidea and extensive 
peer reviewed scientific literature strongly indicate that Tc  99m tilmanocept can enable non -
invasive imaging of aggregates of CD206 expressing cells associated with various pa thologies 
using planar scintigraphy. While it  has been suggested that synovial biopsy and IHC 
evaluations might be translatable to common rheumatological clinical practice, there  are 5 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 21 of 74 
 reasons why quantitative assessment of CD206 positivity enabled by Tc  99m tilmanocept 
imaging may be preferred to synovial biopsies for evaluations of RA patients. 
First, biopsy procedures usually sample a single joint. If variation exists between the 
pathotypes of different joints in the same patient, biopsy studies cannot detect or quantify this variation. Current RA therapies and new therapies in development are, by their designed targets, likely to be more effective against specific RA pathotypes. If pathotype variation occurs within individual RA patients, this could seve rely limit the ability of pathotype 
determination by biopsy to accurately predict treatment response. A key advantage of Tc 99m tilmanocept imaging over synovial biopsies is that Tc 99m
 tilmanocept imaging can provide a 
global quantitative assessment of all joints, providing Tc 99m tilmanocept imaging with the 
possibility of detecting pathotype variation without biopsies. Navidea‚Äôs proposed studies will directly assess RA inflammatory variation within individual patients and provide evidence relevant to det ermining the extent to which pathotype variation exists within individual RA 
patients and the ability of Tc 99m
 tilmanocept imaging to detect this variation.  
The second reason why Tc 99m tilmanocept imaging may be preferred to synovial biopsies for 
evaluations of RA patients is that synovial biopsies are only performed on patients with inflamed synovia that have expanded in volume beyond a certain grade, thereby enabling extraction of sufficient tissue to assess histologically. This could be a problem when evaluating 
patients in the early phase of symptomatic RA disease when high densities of activated macrophages have begun to aggregate into the inflamed synovial membrane but the synovial membrane may not yet have expanded (i.e. thickened) sufficiently to permit biopsy sampling. As discussed below, there is an urgent need to more accurately identify RA patients as early in the disease process as possible and place them on DMARD therapy immediately to provide these patients with their best possible therapy responses.  
The third reason why Tc 99m tilmanocept imaging may be preferred to synovial biopsies for 
evaluations of RA patients is that, although synovial biopsy procedures typically extract 6-14 samples of tissue from each biopsied joint, in about 5% to 10% of cases, they do not provide tissue of sufficient quantity or quality to enable adequate histological evaluations of the inflamed synovial tissue [ 31, 51]. It is expected that Tc 99m tilmanocept imaging would not 
fail to quantitatively assess the aggregation of macrophages in RA inflamed joints at this frequency.  
The fo urth reason is that  although more than 1 biopsy procedure can be performed on an 
individual joint, there are likely to be limitations on the number of times or how often a single 
joint can be biopsied. Furthermore, while not discussed in the literature, repeated biopsies may alter the inflammatory microenvironment in an inflamed synovial membrane and/or induce its own inflammation or wound healing response to trauma. In any event, Tc  99m tilmanocep t 
imaging, being non- invasive and non- traumatic, is likely to be more amenable to repeat 
examination and would not affect synovial inflammation through repeated biopsy related trauma. These issues may be most significant when considering evaluations of the  small joints 
of the hands where there is a limited quantity of inflammatory tissue.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 22 of 74 
 The fifth and final reason why Tc 99m tilmanocept imaging  will be preferred to synovial 
biopsies is that performing biopsies is challenging and requires extensive training [52]. 
Synovial biopsies have only been performed in research settings and until very recently, only 
in Europe where adequately trained and experienced investigators reside. Training and qualifying all physicians in the US who care for RA patients to perform synovial biopsies would be a significant barrier to adoption.  
Indeed, Tc 99m t ilmanocept quantitative imaging reliably assesses  all joints, is not dependent 
on synovial swelling, is non- invasive and non- traumatic , and does not require extensive 
practitioner training . Thus, for all these reasons, Tc 99m tilmanocept imaging is e xpected to  
provide clinically predictive  information about the inflammatory status of inflamed joints in 
RA patients that is not obtainable from  synovial biopsies or will be preferred over invasive and 
potentially risky synovial biopsies as a means to eval uate RA patients.  
In diagnostic radiology, quantitative imaging provides a layer of clinically meaningful 
information beyond that of qualitative interrogation. The Radiological Society of North America (RSNA) defines quantitative imaging as ‚Äúthe extraction of quantifiable f eatures from 
medical images for the assessment of normal or the severity, degree of change, or status of a disease, injury, or chronic condition relative to normal. Quantitative imaging includes the development, standardization, and optimization of anatomical, functional, and molecular imaging acquisition protocols, data analyses, display methods, and reporting structures. These features permit the validation of accurately and precisely obtained image -derived metrics with 
anatomically and physiologically relevant parameters, including treatment response and outcome, and the use of such metrics in research and patient care.‚Äù [ 55] 
In nuclear medicine, the SUV (standard uptake value) is an established quantitative imaging metric for the assessment of disease -related activity across a variety of neurological, 
cardiovascular, oncological, and immunological conditions. For example, in 18F- labeled 
fluoro -2-deoxyglucose positron emission tomography (
18F- FDG PET ) imaging, SUV is used 
to measure the proliferative activity of malignant tumors in various cancers through the quantification of FDG uptake using the following parameters: r, the radioactivity activity concentration [kBq/mL] measured by the PET scanner within a region of interest (ROI), a‚Äô, the decay -corrected  amount of injected radiolabeled FDG [kBq], and w, the weight of the 
patient [g], such that such that SUV =  r
(a‚Ä≤/w). [56]   
Based on the clinical utility of SUV in 18F- FDG PET imaging, Navidea pursued the 
development of the TUV to quantify CD206 activity on planar gamma camera imaging. TUV considers the fundamental principles of SUV and introduces modifications to account for inter - 
and intra -patient variability and disease pathobiology. After the evaluation of several formula 
permutations, Navidea has established TUV as a metric for the measurement of joint -specific 
CD206 activity in RA through the quantification of Tc 99m tilmanocept uptake using the 
following parameters: ùë•ùë•ÃÖ, the average pixel intensity of a n ROI, and B , the average pixel 
intensity of the whole hand and part of the forearm on the same view and side as the joint ROI 
(serving as an intra -patient reference region), such that TUV =xÔøΩ
B. The overall purpose of this 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 23 of 74 
 study will be to establish the mean and variance of healthy control joint uptake values for 
reference to be used to assess RA -inflamed joints in patients with RA.  
1.2 Previous Nonclinical Research and Clinical Trial Experience in Tc 
99m Tilmanocept  
A detailed evaluation of th e nonclinical evaluations from subcutaneous (SC) and IV routes of 
administration, clinical pharmacokinetics (PK), clinical efficacy, and clinical safety of Tc 99m 
tilmanocept can be found in the accompanying Investigator‚Äôs Brochure supplied by Navidea 
Biopharmaceuticals, Inc.   
1.2.1  Nonclinical Evaluations ‚Äì Subcutaneous  Administration  
Nonclinical studies of Tc 99m  tilmanocept demonstrated that the drug selectively binds to its 
intended receptor (the CD206 mannose binding receptor), and is well tolerated by rats, rabbits, 
guinea pigs, and dogs. 
PK data obtained from nonclinical studies demonstrated rapid absorption into the plasma. 
Urinary excretion was a major pathway of elimination. Tc 99m tilmanocept  exhibited rapid 
clearance from the injection site, rapid uptake by the local lymph node, and low uptake by the 
remaining lymph nodes. Tilmanocept was well tolerated at all doses tested in nonclinical safety pharmacology studies and in single and repeated dose toxicology studies in rats, rabbits, and dogs. In some studies in rabbits and dogs, tilmanoce pt acted as a local irritant of the subcutis 
or skeletal muscle, and induced mild inflammation and tissue degeneration. The no-observed adverse -effect level (NOAEL) was 42Œºg/kg/day. Tilmanocept was not mutagenic or genotoxic 
in vitro or in vivo. No signs or symptoms of hypersensitivity were observed in a study in guinea pigs.  
1.2.2  Nonclinical Evaluations ‚Äì IV Administration  
In preparation to initiate the IV route of administration, 11 preclinical tests were conducted to 
assess safety, toxicity, and interaction potential at doses hundreds to thousands of times the expected maximum human dose, as summarized in Table 1. The nonclinical evaluations 
yielded safety and pharmacokinetics profiles that were appropriate for initiation of IV dosing in clinical trials. Nonclinical study results can be found in the accompanying Investigator‚Äôs Brochure. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 24 of 74 
 Table  1  Preclinical Tests  
Type of Study / 
Description  Test System  Method of 
Administration  Dosing  
Central nervous system 
safety pharmacology  Rat Intravenous  37, 190, and 380 ¬µg/animal 
or equivalent 490X and 61X 
the anticipated study doses 
of 50 ¬µg and 400 ¬µg in 
humans  
Expanded single -dose 
toxicology (including toxicokinetics and local tolerance)  Rat Intravenous  37, 190, and 380 ¬µg/animal 
or equivalent 490X and 61X 
the anticipated study doses 
of 50 ¬µg and 400 ¬µg in 
humans  
Respiratory Safety 
Pharmacology 
Evaluation Using Head -
Out Plethysmography of 
Tilmanocept following Intravenous Bolus Injection in Male Rats  Rat Intravenous  60, 120, and 300 ¬µg/animal 
or equivalent 320X and 41X 
the anticipated study doses 
of 50 ¬µg and 400 ¬µ g in 
humans  
In Vitro Evaluation of 
Tilmanocept as an Inhibitor of Cytochrome P450 (CYP) Enzymes in Human Liver Microsomes  Human Liver 
Samples  In vitro  0.6 to 600 nM  
In Vitro Evaluation of 
Tilmanocept  as an 
Inhibitor of Human ABC and SLC Transporters  Human Liver 
Samples  In vitro  0.04, 0.4 ¬µM  
Pharmacokinetics, 
Excretion, and Distribution by  
Quantitative Whole -
Body Autoradiography  
Following Intravenous Administration of  
99mTc -Tilmanocept in 
Rats Rat Intravenous  25 ¬µg in 0.5 mL with 
collection of  blood, urine, 
feces, and c arcasses for 
QWBA  
Hemolysis and protein flocculation  Human blood 
samples  In vitro  2.5, 25, and 250 ¬µg/mL 
whole human blood  
Target profiling screen  
(K, Na, and Ca ion channels)  Ion Channel  In vitro  0.025  to 0.5 mg/mL  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 25 of 74 
 1.2.3  Clinical Pharmacokinetics (IV) 
Clinical PK was evaluated in IV administered Tc 99m tilmanocept in the Phase 1 and 2 trial 
NAV3 -21 ([STUDY_ID_REMOVED]). In this  trial, 12 subjects (6 RA/6 HC) were administered the 
maximum dose of 400 mcg  tilmanocept radiolabeled with 10 mCi of Tc 99m  and urine and 
blood data were non -compartmentally modeled to assess potential differences in drug 
distribution and elimination by disease group (active RA vs. HC ). 
Subject -level whole blood PK parameters were assessed between HC subjects (n  = 6) and 
subjects with active RA (n  = 6) to evaluate potential differences between mean maximum 
concentration (C max), mean area under the concentration -time curve (AUC 0-t), mean area under 
the concentration -time curve extrapolated to infinity (AUC 0-‚àû), mean clearance, mean half -life 
(t1/2), or mean elimination rate constant ( Œªz) across each disease group ( Table 2).  The geometric 
mean of whole blood clearance was 26.5 mL/min for HC subjects and 24.8 mL/min for RA patients.  
Table  2  Whole Blood PK Parameter Summaries by Group 
Group  Statistic  Clearance 
(mL/min)  AUC(0 -t) 
(min*nCi)  AUC(0 -‚àû) 
(min*nCi)  Cmax 
(nCi)  T1/2  
(min)  
HC n 6 6 6 6 6 
Mean  27.3 235258.0  370580.1  1244.2  759.0  
Std Dev  7.36 50010.28  92535.92  500.36  134.20  
CV%  26.9 21.3 25.0 40.2 17.7 
Geometric 
Mean  26.5 230853.1  360357.6  1155.5  749.3  
Lower 90% 
CI 21.26  193698.75  290005.04  809.55  648.36  
Upper 90% 
CI 33.04  275134.27  447777.17  1649.33  865.85  
RA n 6 6 6 6 6 
Mean  25.5 268110.7  396026.4  2043.8  719.1  
Std Dev  6.18 61667.51  101351.07  1211.86  138.10  
CV%  24.3 23.0 25.6 59.3 19.2 
Geometric 
Mean  24.8 262309.5  385984.3  1761.9  707.4  
Lower 90% 
CI 20.11  217187.41  315475.79  1078.28  598.97  
Upper 90% 
CI 30.59  316806.03  472251.44  2878.94  835.46  
 Similarly, subject- level urinary PK parameters including maximum rate, AUC
0-t, or percent 
recovered were assessed for HC subjects (n=6) and subjects with active RA (n=6) to evaluate potential differences between disease groups (Table  3). The geometric mean of urine percent 
recovered was 7.4% in HC subjects and 6.7% in RA patients.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 26 of 74 
 Table  3  Urine PK Parameter Summaries by Group  
Group  Statistic  Percent 
Recovered a AUC(0 -t) 
(h*nCi)  Max Rate 
(nCi/h) b 
HC n 6 6 6 
Mean  7.6 1468788.9  949280.7  
Std Dev  2.07 432723.27  236916.28  
CV%  27.2 29.5 25.0 
Geometric Mean  7.4 1411786.8  924858.6  
Lower 90% CI  5.84 1088888.09  752742.08  
Upper 90% CI   9.28 1830437.75  1136329.94  
RA n 6 6 6 
Mean  6.9 1384642.0  841331.0  
Std Dev  1.74 313600.65  227308.94  
CV%  25.2 22.6 27.0 
Geometric Mean  6.7 1355137.9  817282.6  
Lower 90% CI  5.46 1123310.11  659111.71  
Upper 90% CI  8.33 1634810.07  1013410.74  
a Percent recovered is the cumulative amount of radioactivity divided by the dose and multiplied by 100.  
b Maximum observed excretion rate, calculated as (radioactivity*volume)/ (end time ‚Äì start time). 
 
A comparison of the PK parameters in subjects with active RA and HC subjects does not reveal 
any apparent differences in the elimination of radioactivity from the body. 
1.2.4  Clinical Efficacy  
1.2.4.1  NAV3 -23 (SC)  
This was an open- label, multicenter study of Tc  99m tilmanocept by subcutaneous injection in 
patients with active RA and healthy controls.  Tilmanocept was administered SC at 1 of 2 mass 
doses: [1] 50 mcg (Cohorts 1 & 3), or [2] 200 mcg (Cohorts 2 & 4). Both mass doses were 
radiolabeled with 2 mCi of Tc 99m. A total of 18 subjects were enrolled and evaluated (9 active RA, 9 HC). Imaging was performed 60 ¬± 15 minutes post injection. The following performance conclusions were drawn  upon study completion:  
‚Ä¢ Based on data from this study and parallel pathology studies, Tc 99m tilmanocept localizes to activated macrophage- infiltrated joints at doses of 50 ¬µg and 200 ¬µg 
radiolabeled wit h 2.0 mCi (74.0 MBq) by SC administration.  
‚Ä¢ Across all combined RA subjects, swollen/tender joints demonstrating the highest proportions of localization include the wrists and knees.  
‚Ä¢ Based on qualitative image evaluation, Tc 99m tilmanocept does not show differences 
in localization between 2  to 3 and 4 to  6-hour planar imaging within dosing groups.  
‚Ä¢ Tc 99m tilmanocept demonstrates a greater frequency of localization to swollen/tender 
joints at 200 mcg /2.0 mCi than 50 mc g/2.0 mCi.  
‚Ä¢ There is an overall lack of concordance between qualitative observation of Tc 99m 
tilmanocept localization to swollen/tender joints identified in DAS28 joint count 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 27 of 74 
 assessment. Swollen/tender joints did not appear to be reliable predictors of presumed 
abnormal activated macrophage infiltration and overall disease progression when used as an isolated diagnostic system.  
‚Ä¢ Increased tilmanocept mass dosing, increased Tc 99m specific activity, and other routes of administration may enhance localization and anatomic delineation in tilmano cept-
positive joints of RA patients.  
‚Ä¢ The potential for using Tc 99m tilmanocept to delineate macrophage infiltration in RA -
affected joints may allow for earlier RA -specific treatment beyond the current standard 
of care ACR/EULAR criteria.  
 
1.2.4.2  NAV3 -21 (IV)  
This was an open -label, multicenter, dose -escalation safety with PK and dosimetry study of 
Tc 99m tilmanocept by IV injection in HCs and subjects  with active RA. Thirty -nine subjects 
were enrolled. A total of 27 subjects with active RA were enrolled to Groups 1 to 9 in the dose escalation phase. Group 10 consisted of 6 HCs (3 female and 3 male) and Group 11 consisted of 6 subjects with active RA (3 female and 3 male). Tilmanocept was administered IV at 1 of 3 mass doses: 50 mcg, 200 mcg, or 400 mcg.  Within each mass dose group, tilmanocept was radiolabeled with 1 of 3 Tc 99m doses: 1 mCi, 5 mCi, or 10 mCi.  Subjects in Groups 10 and 
11 received the maximum dose of 400 mcg/10 mCi. Imaging was performed 60 ¬± 15 minutes 
p.i. The following clinical efficacy concl usions were drawn upon study completion: 
‚Ä¢ The TUV
brain(average) readout provides an objective means of quantification of Tc 99m 
tilmanocept localization when administered at the calculated optimal dose of 150 mcg/10 mCi and planar images are acquired 60 to 180 minutes after drug administration.  
‚Ä¢ Joint- specific localization of activity and joint- specific clinical symptomology were not 
fully concordant. Within the spectrum of RA disease involvement, there may be a decoupling of the causal active immune process  and subsequent clinical sequelae. We 
surmise that imaging and quantification of Tc 99m tilmanocept uptake may provide a fuller and more accurate, responsive, and objective measure of RA disease activity than can be obtained from clinical assessments alone. Future studies will examine whether the approach to image acquisition and calculation of TUV can be further refined. 
1.2.4.3  NAV3 -31 (IV)  
This is an ongoing open- label, multi- center,  single and repeat-dose study designed to 
evaluate the reliability and sensitivity of TUV assessments in HCs and subjects with active RA. One -hundred and five evaluable subjects will be enrolled. Tilmanocept is administered 
IV at a dose of 150 mcg tilmanocept radiolabeled with 10 mCi Tc 99m. Clinical efficacy conclusions for this study are still in progress.  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 28 of 74 
 1.2.5   Clinical Safety  
1.2.5.1  NAV3 -23 (SC)  
The NAV3 -23 ([STUDY_ID_REMOVED]) safety evaluation included all trial subjects injected with Tc 
99m tilmanocept (N  = 18). The AE monitoring was performed from the time of dose 
administration until completion of onsite safety assessment. There was 1 AE that was possibly 
related to and 1 AE that was probably related to Tc 99m tilmanocept. However, there were no 
AEs that led to trial discontinuation , and no SAEs were observed. There were no deaths on 
trial. 
1.2.5.2  NAV3 -21 (IV)  
The primary safety endpoint of the NAV3 -21 study was evaluated by exa mining the incidence 
of AEs, changes over time in clinical laboratory tests,  physical exams, electrocardiogram 
(ECG ) parameters,  and vital signs.  The safety evaluation included all subjects who were 
enrolled in the study and administered Tc 99m tilmanocept (n = 39). There were no Tc 99m 
tilmanocept related AEs . There were no deaths during the trial; no SAEs; and no AEs that led 
to discontinuation from the trial.  In addition, radiation exposure was within regulatory and 
safety limits at the doses evaluated. Radiation exposure and pharmacokinetics do not appear to differ in subjects with RA and healthy control subjects. 
1.2.5.3  NAV3 -31 (IV)  
This is an ongoing open- label, multi- center,  single and repeat-dose study designed to 
evaluate the reliability and sensitivity of TUV assessments in HCs and subjects with active RA. One -hundred and five evaluable subjects will be enrolled. Tilmanocept is administered 
IV at a dose of 150 mcg tilmanocept radiolabeled with 10 mCi Tc 99m. Clinical safety conclusions for this study are still in progress.  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 29 of 74 
 2 STUDY OBJECTIVES  
2.1 Primary Objective(s)  
‚Ä¢ To establish mean and variance of TUV joint in HCs age-matched to RA population.  
‚Ä¢ To assess the feasibility of detecting Tc 99m tilmanocept anatomic localization using 
SPECT/CT imaging of hands and wrists in HCs and subjects with active RA.   
 
2.2 Secondary Objective(s)   
‚Ä¢ To quantitate Tc 99m tilmanocept anatomic localization based on  SPECT/CT 
imaging of hands and wrists in HCs and joints with RA-involved inflammation. 
 
2.3 Safety Objective(s)  
‚Ä¢ To evaluate safety through the examination of AE incidence and changes over time in 
laboratory tests, vital signs, and physical examination findings. 
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 30 of 74 
 3 INVESTIGATIONAL PLAN  
3.1 Overall Study Design and Plan 
This is a prospective, open- label, multicenter, single -dose study designed to develop a 
normative database of TUV joint in HCs and to assess the feasibility of qualitative and 
quantitative SPECT/CT assessments in HCs and subjects with active RA  following Tc 99m 
tilmanocept administration . Subjects  will be enrolled in 1 of 2 study arms  (Table 4) with 
distinct study procedures in accordance with  Arm -specific eligibility requirements.  
Table  4  Study Arms  
Arm  n Subjects  Evaluation(s)  
1 120 HCs HC subjects clinically free of any 
inflammatory disease and/or joint pain  Planar image of 
bilateral 
hands/wrists  
2 5 HCs  
10 RA HC subjects clinically free of any inflammatory disease and/or joint pain and subjects with clinically diagnosed active RA who have been on stable anti- rheumatic 
therapy  Planar image of 
bilateral hands/wrists 
 
SPECT/CT of bilateral 
hands/wrists  
 
3.1.1  Arm 1:  No Inflammatory and/or Joint Disease (HC  Subjects ) 
3.1.1.1  Description of Patient Population 
This arm  will be comprised of  120 HCs who are deemed to be clinically  free of inflammatory 
disease(s) and /or arthropathies and clinically free of joint pain for at least 28 days prior to the 
consent date . These subjects will not receive any  anti-inflammatory treatment (s) (including 
NSAIDs) during study participation  and will not have taken any such drugs  at least  28 days 
prior to the consent date . All other concomitant medications  (for non- inflammatory conditions ) 
will have  been maintained at a  stable dose for at least 28 days prior to consent. 
3.1.1.2  Overview of Study Procedures  
Subjects in this arm will have a total of  two on-site visits and one telephone safety assessment. 
The maximum possible study duration for these subjects will be 39 days.  
3.1.1.3  Justification for Population 
The reason for the inclusion  of this  study population is to establish mean and variance for 
TUV joint values in HCs to develop a normative database to which the inflamed joints of subjects 
with active RA can be compared . By determining the upper limit of normal (ULN) for  average 
anterior or posterior TUV joint for right and left joints of the bilateral hands and wrists, these 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 31 of 74 
 assessments can be further investigated for their utility in  providing clinically meaningful 
reference data for symptomatic  individuals presenting to the clinic.  
3.1.2  Arm 2:  HCs and RA Subjects  on Stable  Anti-Rheumatic  Therapy   
3.1.2.1  Description of Patient Population 
This arm will include five  (5) HCs who are deemed to be clinically free of inflammatory 
disease(s) and /or arthropathies and clinically free of joint pain for at least 28 days prior to the  
consent date . These subjects will not receive any anti -inflammatory treatment(s) (including 
NSAIDs) during study participation and will not have taken any such drugs  at least 28 days 
prior to the consent date. All  other concomitant medications  (for non -inflammatory conditions) 
will have  been maintained at a  stable dose for at least 28 days prior to consent. 
This arm will also include ten  (10) subjects with clinically diagnosed active RA on stable anti -
inflammatory and/or anti -rheumatic therapy.  All subjects‚Äô RA  diagnoses will be moderate to 
severe in accordance with a 2010 ACR/EULAR score of 6 or higher. All  subjects receiving 
traditional DMARDs must have been on therapy for ‚â•  90 days and at  a stable dose for ‚â•3 0 
days prior to the first imaging visit; all subjects receiving bDMARDs must have been on 
therapy for at least 60 days prior to the first imaging visit; and all subjects receiving NSAIDs 
and/or oral corticosteroids must have been on therapy for at least 28 days prior to the first 
imaging visit ( Table 7).  
Table  5  Inclusion Criteria Treatment Windows for Recent or Concomitant RA-specific Treatments 
Drug Class  Window  
Traditional DMARDs  On therapy ‚â• 90 days and at a stable dose ‚â• 30 days prior to 
the imaging visit (Day 0) 
bDMARDs  > 60 days prior to the imaging visit (Day 0)  
JAK inhibitors  > 60 days prior to the imaging visit (Day 0)  
NSAIDs/Corticosteroids  ‚â• 28 days prior to the imaging visit (Day 0)  
 
3.1.2.2  Overview of Study Procedures  
Subjects in this arm will have a total of two  on-site visits and  one telephone safety assessment. 
The maximum possible study duration for these subjects will be 39 days.  
3.1.2.3  Justification for Population 
The reason for the inclusion of this study population is to assess the feasibility of qualitative and quantitative SPECT/CT assessments following Tc 99m tilmanocept administration. HCs will provide control data to which data from RA subjects on stable therapy can be compared. Planar imaging from these subjects will be utilized for comparison to SPECT/CT results and will be pooled with data from this and previous Navidea RA trials for TUV evaluation s.   
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 32 of 74 
 3.2 Protocol Adherence 
Strict adherence to all specifications outlined in this protocol is required for all aspects of the 
study conduct; the investigator may not modify or alter the procedures described in this protocol. If protocol modifications are necessary, all alterations that are not solely of an administrative nature require a formal protocol amendment for the involvement of Institutional Review Board(s) (IRB(s)).  
If an investi gator has deviated from the protocol in order to eliminate an immediate hazard to 
subjects or for other inevitable medical reasons, the investigator shall document all such deviations, including the reasons thereof, and submit the document to the sponsor and the IRB as applicable.  
3.3 Study Duration(s) 
The maximum possible study duration for Arm 1 or 2 subjects is  39 days. 
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 33 of 74 
 4 STUDY POPULATION  
4.1 Study Arms 
The study population will be comprised of HC s and  subjects with clinically diagnosed active 
RA on stable anti- rheumatic therapy . Subjects will be enrolled in 1 of 2 study arms ( Table 6 ): 
Table  6  Study Arms  
Arm  n Subjects  Evaluation(s)  
1 120 HCs HC subjects clinically free of any 
inflammatory disease and/or joint pain  Planar image of 
bilateral 
hands/wrists  
2 5 HCs  
10 RA HC subjects clinically free of any inflammatory disease and/or joint pain and subjects with clinically diagnosed active RA who have been on stable anti- rheumatic 
therapy  Planar image of 
bilateral hands/wrists 
 
SPECT/CT of bilateral 
hands/wrists  
 
4.2 Eligibility 
All inclusion/exclusion criteria must be verified before any subject is considered eligible for enrollment and for administration of Tc 99m tilmanocept and imaging (Day 0 procedures). Subjects will be considered enrolled once injected with Tc 9 9m tilmanocept  (Day 0). Written  
and dated (with time -noted) informed consent will be obtained from all subjects. A subject 
who withdraws consent prior to receiving Tc 99m tilmanocept injection  on Day 0 will be 
considered a screen failure.   
4.2.1  Inclusion Criteria  
ALL SUBJECTS  
1. The subject has provided written informed consent with HIPAA authorization before 
the initiation of any study- related procedures.  
2. The subject has agreed to not engage in any diet, lifestyle, or medication changes until study completion.  
 
HEALTHY CONTROL SUBJECTS  
3. The subject is 30 years of age or greater at the time of consent.  
4. The subject is deemed to be clinically free of any inflammatory disease (s), auto-
immune disease(s), or arthropathies and has not experienced joint pain for at least 28 
days prior to the consent date. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 34 of 74 
 5. The subject is not currently on anti -inflammatory drugs (including NSAIDs) and has 
not taken any anti -inflammatories for at least 28 days prior to the consent date.  
6. For all ongoing concomitant medications, the subject has maintained a stable dose for 
at least 28 days prior to the consent date. 
 
CLINICALLY DIAGNOSED ACTIVE RA SUBJECTS  
3. The subject is at least 18 years of age and was ‚â• 18 years of age at the time of RA diagnosis. 
4. The subject has moderate to severe RA as determined by the 2010 ACR/EULAR Classification Criteria  (score of ‚â• 6/10).  
5. The subject has a D AS28 of ‚â• 3.2 (includes the ESR test and VAS) . 
6. If the subject is receiving traditional DMARDs , they have been on therapy for 
‚â• 90 days and at a stable dose for ‚â• 30 days prior to the imaging visit (Day 0).  
7. If the subject is receiving bDMARD or JAK inhibitor  therapy, they have been at a 
stable dose > 60 days prior to the imaging visit (Day 0).  
8. If the subject is receiving NSAIDs or
 oral corticosteroids, the dose has been stable for 
‚â• 28 days prior to the imag ing visit (Day 0). The corticosteroid dose must be ‚â§ 
10mg/day of prednisone or an equivalent steroid dose. 
 
4.2.2  Exclusion Criteria  
1. The subject is pregnant or lactating.  
2. The subject  size or weight is not compatible with imaging per the investigator . 
3. The subject is currently receiving radiation therapy or chemotherapy or has received 
radiation therapy or chemotherapy in the past six months. 
4. The subject has had a finger, hand, and/or wrist amputation or hand or wrist joint 
arthroplasty. 
5. The subject has renal insu fficiency as demonstrated by a glomerular filtration rate  of 
< 60 mL/min.  
6. The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST  (aspartate aminotransferase [SGOT])  greater than 
2 times the upper limit of normal. 
7. The subject has any severe, acute, or chronic medical  conditions and/or psychiatric 
conditions and/or laboratory abnormalities  that would impart, in the judgment of the 
investigator, excess risk associated with study participation or study drug 
administration  that would deem the subject inappropriate for study participation or 
compromise the safety of the subject or the quality of the data. 
8. The subject has any unstable medical illnesses , including hepatic, renal, 
gastroenterologic, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 35 of 74 
 9. The subject has a known allergy to or has had an adverse reaction to dextran exposure. 
10. The subject has received an investigational product within 30 days prior to Tc 99m 
tilmanocept administration  (Day 0). 
11. The subject has received intra- articular corticosteroid injections ‚â§ 8 weeks prior to Tc 
99m tilmanocept administration  (Day 0) . 
12. The subject has received any radiopharmaceutical within 7 days or 10 half -lives prior 
to Tc 99m tilmanocept administration  (Day 0). 
13. Healthy Controls only: The subject has a positive rheumatoid factor and an elevated 
ESR or CRP.  
 
4.3 Recruitment 
Healthy control subjects will be recruited via clinical research sites and clinically assessed for the ‚Äúabsence‚Äù of painful and/or swollen joints. RA s ubjects will be recruited from 
rheumatology practices in accordance with the inclusion and exclusion criteria listed above. Candidate subjects will be asked by their treating physician about their willingness to 
participate in the study.  
4.4 Withdrawal 
In accordance with the Declaration of Helsinki, each subject is free to withdraw from the study at any time and without providing a reason.  
A subject who withdraws consent prior to receiving Tc 99m tilmanocept injection on Day 0 
will be considered a screen failure.  
Should a subject withdraw after administration of the investigational product, all efforts will be made to complete and report the observations up to the time of withdrawal as thoroughly as possible. An explanation should be given of why the subject is withdrawing or being withdrawn from the study. 
The investigator may withdraw a subject from the study at any time at the discretion of the 
investigator for any of the following reasons:  
‚Ä¢ A protocol violation occurs  
‚Ä¢ A serious or intolerable AE occurs  
‚Ä¢ A clinically significant change in a laboratory parameter occurs  
‚Ä¢ At the investigator‚Äôs/sponsor‚Äôs discretion as long as it is in the best interest of the subject  
‚Ä¢ The sponsor or investigator terminates the study  
‚Ä¢ The subject requests to be discontinued from the study  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 36 of 74 
 4.5 Replacement 
Subjects will be replaced if they have not completed all study procedures necessary for the 
primary endpoint (s) relevant to their study arm  or their data are determined to be  not evaluable. 
A subject is considered evaluable if he/she meets the criteria for the analysis population and has the data necessary for computing the primary endpoint.
 
 
4.6 Screen Failures  
Subjects who sign an informed consent form (ICF) but are ultimately not injected will be considered a screen failure. Subjects  will be assigned a study identification number at the time 
the ICF is signed. e CRF s for Informed Consent, Inclusion, Exclusion, Demo graphic s, Adverse 
Events, and final disposition should be co mpleted  for all screen failure subjects.  
4.7 Subject Identification 
After the subject provides written informed consent, the site will assign the subject a 7 -digit 
subject number. Subject numbers are to be assigned in a sequential manner using the following format:  
Digits 1 to 2 : Study number ‚Äú35 ‚Äù  
 
Digits 3 to 4 : Site number (e.g., ‚Äú01‚Äù)  
 
Digits 5 to 7 : Sequential subject number (e.g., ‚Äú001‚Äù, ‚Äú002‚Äù, ‚Äú003‚Äù)  
For example, the first subject consented at Site 01 is subject number ‚Äú35-01-001.‚Äù  
 
Subjects will maintain the same number given at screening for the entire  study. If a subject is 
a screen failure, the number will not be used for any other subject. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 37 of 74 
 5 INVESTIGATIONAL PRODUCT  
5.1 Description of Investigational Project 
Technetium Tc 99m tilmanocept is a scintigraphic imaging radiotracer that  binds to CD206 
(mannose-binding receptor ) on the surface of macrophages and other inflammatory cells . It is 
comprised of  multiple units of DTPA (diethylenetriaminepentaacetic acid) and mannose, each 
synthetically attached to a 10 kDa dextran backbone  (Figure  1). The mannose acts as a 
substrate for the receptor and the DTPA serves as a chelating  agent for labeling with Tc 99m . 
Tilmanocept  has a diameter of about 7 nm, which permits enhanced diffusion into lymph nodes 
and blood capillaries.  
Figure  1  Tc 99m tilmanocept and the Mannose Receptor  
 
 
5.2 Investigational Product Dosage and Administration 
Tc 99m tilmanocept will be administered  through an IV  route of injection. A 150- mcg dose 
containing 10 mCi of Tc 99m in 3 mL will be delivered using 1 syringe. The dose will be  
injected as a slow push into the IV catheter . At the completion of the injection, a 10- mL sterile 
normal saline flush will be administered.  The preferred site of IV placement will be between 
the left or right antecubital vein . 
The final administered dose will be ¬± 20% of the tilmanocept mass dose and radiolabel mCi 
dose. 

Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 38 of 74 
 5.3 Timing and Frequency of Drug Administration 
Subjects in either  arm will receive the study- defined dose of 150 mcg tilmanocept radiolabeled 
with 10 mCi of Tc 99m on Day 0 Visit 2.  
 
5.4 Packaging and Labeling 
Tilmanocept  cartons ready for radiolabeling will be shipped and stored at the study- assigned  
radiopharmacy. Tilmanocept is provided in a vial. Vials are packaged as a kit. A carton (kit) 
contains 5 vials of tilmanocept.  
A detailed Radiolabeling protocol will be prov ided to each radiopharmacy for instructions on 
how to radiolabel the vials and prepare the final tilmanocept product for injection. Quality Control worksheets will also be provided. 
5.5 Drug Logistics and Investigational Product Accountability 
The investigator  (or designated personnel) will confirm receipt of the investigational product 
in writing and will use the investigational product only within the framework of this clinical study and in accordance with this study protocol. For each subject, he/she will ke ep a record 
of the investigational product dispensed and store all other forms that accompanied the delivery of the radiolabeled product to the clinical site. These documents are to be filed in the investigator site file. Overall drug accountability and re conciliation will be completed by the 
sponsor or its representative. A list of investigational product vials and other materials that were returned, or destroyed, must be recorded and signed by the PI or an appropriately qualified designee as documented in  the study site responsibility sheet. An overall 
accountability and reconciliation form of the investigational product will be prepared and completed. If there are any discrepancies, they must be investigated and their resolution documented. All unused study kits will be destroyed in accordance with institutional destruction procedures. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 39 of 74 
 6 THERAPIES OTHER THAN INVESTIGATIONAL PRODUCT 
6.1 Prior and Concomitant Therapies 
All medications taken 30 days prior to Tc 99m tilmanocept injection through the post -injection 
safety follow -up must be documented  and maintained at a stable dose according to the 
inclusion criteria . Subjects receiving  radiation therapy or chemotherapy are not eligible for 
participation in the trial.  If applicable, the subject‚Äôs  history of RA  treatme nts for up to 6 months 
will also be collected . 
6.2 Post-Study Therapy 
There are no post-study therapy restrictions. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 40 of 74 
 7 STUDY PROCEDURES 
A schedule of evaluations is provided in the s chedule of events ( Appendix 1).  
7.1 Schedule of Evaluations 
7.1.1  Arm 1   
Visit 1 (Screening; Day -30 to Day -1) 
‚Ä¢ Preliminary review of inclusion and exclusion criteria 
‚Ä¢ Obtain signed informed consent for study participation 
‚Ä¢ Allocation of unique subject number; this number will be used to document the subject 
data in the case repo rt forms (CRFs) and enrollment log 
‚Ä¢ Demography ‚Äì date of birth, gender, race, ethnicity  
‚Ä¢ Medical surgical history ‚Äì all relevant prior medical and surgical conditions will be 
recorded in the CRF. Documented medical conditions will also note the month and ye ar 
of onset if the condition is still active.  
‚Ä¢ Concomitant medications (within 30 days before injection). 
‚Ä¢ Vital sign s (body temperature, heart rate, blood pressure, and respiratory rate after at 
least 1 minute in a resting position)  
‚Ä¢ Physical exam ination  will include an assessment of height, weigh t, and examination of 
general appearance, skin, eyes, ears, nose, throat, head and neck (including thyroid), 
lungs, heart, abdomen, lymph nodes, musculoskeletal, and nervous system. Any clinically relevant finding is to be documented as a baseline finding. Physical exams that are conducted as standard of care prior to signing informed consent may be used if they are performed within 30 days of injection. 
‚Ä¢ Clinical laboratory tests ‚Äì study subjects will have blood obtained for hematology, 
chemistry, and an  RA panel (see Table 7)   
‚Ä¢ Urine collection for routine analysis 
‚Ä¢ Urine pregnancy test for women of child- bearing potential. Females of child bearing 
potential are defined as women that are not surgically sterile (hys terectomy or bilateral 
oophorectomy) nor postmenopausal for at least 1 year prior to screening. Women who are not of childbearing potential will not require a pregnancy test. 
‚Ä¢ 2010 ACR/EULAR : to confirm that the subject is clinically free of inflammatory 
disease and joint pain  Swollen  and tender joints will be identified and documented 
during physical examination as established by the 2010 ACR/EULAR.  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 41 of 74 
 Visit 2 (Tc 99m Tilmanocept Administration and Imaging; Day 0) 
All subjects will be assessed for adverse ev ents in an ongoing manner from the day of injection 
through the end of participation.  
Pre-Tc 99m Tilmanocept Administration  
 The following procedures will be completed for all subjects on the day of injection prior to the administration of Tc 99m tilmanoc ept: 
‚Ä¢ A urine pregnancy test for women of child-bearing potential. Females of child bearing potential are defined as women that are not surgically sterile (hysterectomy or bilateral oophorectomy) nor postmenopausal for at least 1 year prior to screening. Women who are not of childbearing potential will not require a pregnancy test. 
‚Ä¢ Assessment of adverse events 
‚Ä¢ Concomitant medication review  
‚Ä¢ Vital signs after at least 1 minute in a resting position  (body temperature, heart rate, 
blood pressure, and respiratory rate)  within 30 minutes prior to administration of Tc 
99m tilmanocept 
 
Tc 99m Tilmanocept Administration  
 IV administration of Tc 99m tilmanocept will be at study time 00:00. The preferred sit e of IV 
placement will be the left or right antecubital vein . The filled syringe will be connected to the 
catheter  for a slow push injection (30-60 seconds). At the completion of the injection, a 10- mL 
sterile normal saline flu sh will be administered. The IV administration will be performed in 
the nuclear medicine department by an onsite Certified Nuclear Medicine Technologist or Nuclear Medicine Physician. Subjects will be continuously monitored for adverse events. 
0-30 Minutes Post- Tc 99m Tilmanocept Administration  
‚Ä¢ Assessment of adverse events 
‚Ä¢ Vital signs after at least 1 minute in a resting position (body temperature, heart rate, blood pressure, and respiratory rate) 
 
60 - 75 Minutes Post- Tc 99m Tilmanocept Administration  
‚Ä¢ Assessment of adverse events 
‚Ä¢ Image acquisition : Planar scan of the bilateral hands and wrists  acquired per NAV3 -35 
Image Acquisition Guidelines  
 
Visit 3  (Day 5 ¬± 3; Follow- up Telephone Safety Assessment)  
‚Ä¢ Review of concomitant medications  
‚Ä¢ Assessment of adverse events 
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 42 of 74 
 7.1.2  Arm 2  
Visit 1 (Screening; Day -30 to Day -1) 
‚Ä¢ Preliminary review of inclusion and exclusion criteria 
‚Ä¢ Obtain signed informed consent for study participation 
‚Ä¢ Allocation of unique subject number; this number will be used to docum ent the subject 
data in the case report forms (CRFs) and enrollment log 
‚Ä¢ Demography ‚Äì date of birth, gender, race, ethnicity  
‚Ä¢ Medical surgical history ‚Äì all relevant prior medical and surgical conditions will be 
recorded in the CRF. Documented medical conditions will also note the month and year 
of onset if the condition is still active.  
‚Ä¢ Concomitant medications (within 30 days before injection). 
‚Ä¢ Vital sign s (body temperature, heart rate, blood pressure, and respiratory rate after at 
least 1 minu te in a resting position) 
‚Ä¢ Physical exam ination  will include an assessment of height, weight, and an examination 
of general appearance, skin, eyes, ears, nose, throat, head and neck (including thyroid), lungs, heart, abdomen, lymph nodes, musculoskeletal, and nervous system. Any clinically relevant finding is to be documented as a baseline finding. Physical exams that are conducted as standard of care prior to signing informed consent may be used if they are performed within 30 days of injection. 
‚Ä¢ Clinical la boratory tests ‚Äì study subjects will have blood obtained for hematology, 
chemistry, and an  RA panel ( Section 8.8 )  
‚Ä¢ Urine collection for routine analysis 
‚Ä¢ Urine pregnancy test for women of child- bearing potential. Females of child bearing 
potential are defined as women that are not surgically sterile (hysterectomy or bilateral oophorectomy) nor postmenopausal for at least 1 year prior to screening. Women who are not of childbearing potential will not require a pregnancy test. 
‚Ä¢ RA Evaluations : Swollen  and tender joints will be identified and documented during 
physical examination as established by the 2010 ACR/EULAR  for both HCs and RA 
subjects . RA subjects will also undergo a DAS28 evaluation and a  review of RA history 
including previous treatments, date of symptom onset, and date of diagnosis.  
 Visit 2  (Day 0; Tc 99m Tilmanocept Administration and Imaging) 
All subjects will be assessed for adverse events in an ongoing manner from the day of injection through the end of participation.  
Pre-Tc 99m Tilmanocept Administration  
 The following procedures will be completed for all subjects on the day of injection prior to the administration of Tc 99m tilmanocept: 
‚Ä¢ A urine pregnancy test for women of child-bearing potential. Females of child bearing potential are defined as women that are not surgically sterile (hysterectomy or bilateral 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 43 of 74 
 oophorectomy) nor postmenopausal for at least 1 year prior to screening. Women who 
are not of childbearing potential will not require a pregnancy test. 
‚Ä¢ Assessment o f adverse events 
‚Ä¢ Concomitant medication review  
‚Ä¢ Vital signs after at least 1 minute in a resting position  (body temperature, heart rate, 
blood pressure, and respiratory rate)  within 30 minutes prior to administration of Tc 
99m tilmanocept 
 
Tc 99m Tilmanocept Administration  
 IV administration of Tc 99m tilmanocept will be at study time 00:00. The preferred site of IV placement will be the left or right antecubital vein . The filled syringe will be connected to the 
catheter  for a slow push injection (30- 60 seconds). At the completion of the injection, a 10- mL 
sterile normal saline flu sh will be administered. The IV administration will be performed in 
the nuclear medicine department by an onsite Certified Nuclear Medicine Technologist or Nuclear Medicine Physician. Subjects will be continuously monitored for adverse events. 
0 to 30 Minutes Post- Tc 99m Tilmanocept Administration  
‚Ä¢ Assessment of adverse events 
‚Ä¢ Vital signs after at least 1 minute in a resting position (body temperature, heart rate, blood pressure, and respiratory rate) 
 
60 - 75 Minutes Post- Tc 99m Tilmanocept Administration  
‚Ä¢ Assessment of adverse events 
‚Ä¢ Image acquisition (in the following order): 1. Planar scan of the bilateral hands and wrists acquired per NAV3 -35 Image 
Acquisition Guideli nes followed by preparation (up to 10 minutes) for the 
subsequent scan; 
2. SPECT/CT of the bilateral hands and wrists acquired per NAV3- 35 Image 
Acquisition Guidelines 
 Visit 3  (Day 5 ¬± 3; Follow- up Telephone Safety Assessment)  
‚Ä¢ Review of concomitant medications  
‚Ä¢ Assessment of adverse events 
  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 44 of 74 
 8 PROCEDURES AND VARIABLES  
8.1 Population Characteristics 
8.1.1  Demographics and Other Baseline Characteristics  
One-hundred and thirty -five (135) ev aluable subjects will be enrolled across the 2  study arms. 
Arm 1  will be  comprised of 120 male or female HC  subjects  who are clinically free of any 
inflammatory and/or joint disease. Arm 2 will be comprised of 15 subjects. Ten (10) s ubjects 
in Arm 2 will be male or female individuals with clinically diagnosed active RA  who are on 
stable anti -inflammatory and/or anti -rheumatic therapy. Five (5) subjects in Arm 2 will be male 
or female HCs who are clinically free of any inflammatory and/or joint disease. Enrolled HCs 
in either Arm will be categorized by age and sex to ens ure intended distributions are met for 
the normative database, as described in Section 9.4
. 
8.1.2  Medical , Rheumatological,  and Surgical History  
Relevant medical , rheumatological, and surgical histories will be obtained on all study 
subjects.  As part of the medical history, the date of the last spontaneous menstruation will be recorded if  childbearing potential is not excluded by surgical sterilization. Rheumatological 
history will include date of RA diagnosis as well as the  timing , dose, administration frequenc y, 
and administration route (when available)  of all RA -specific drugs  taken in the last 6 months. 
8.1.3  Prior and Concomitant Medication  
All prior non- RA medications used up to 30 days before the first screening examination 
through the follow -up safety visit will be documented . In addition to the summarization of 
prior R A-specific treatments, recent or concomitant treatments taken for RA in the last 6 
months must be collected . 
 
8.2 Tc 99m Tilmanocept Administration 
Tc 99m tilmanocept must  be ordered from the study-assigned radiopharmacy once the subject 
has been scheduled for IV administration and imaging. The preferred site of IV placement will 
be the left or right antecubital vein . The filled syringe will be connected to the c atheter  for a 
slow push injection. Immediately after the completion of the injection, a 10- mL sterile normal 
saline flush will be administered. Injection of Tc 99m tilmanocept will be at study time 0:00.  
8.3 Rheumatological Assessments 
8.3.1  2010 ACR/EULAR Classification Criteria  
All subjects will be evaluated at screening using the 2010 ACR/EULAR Classification Criteria as part of eligibility and inclusion  (Aletaha et . al 2010) . The 2010 ACR/EULAR classification 
criteria includes 4 components: number and site of involved joints, serologic abnormality, 
elevated acute -phase response and symptom duration. See Appendix 5 for details.  A total score 
Technetium Tc 99m tilmanocept  Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 45 of 74 
 of 6 or higher (out of a possible 10) combined with clinical synovitis not better explained by 
another disease confirms a diagnosis of ‚Äúdefinite RA‚Äù. 
8.3.2  DAS28  
RA s ubjects  in Arm 2 will receive the DAS28  evaluation ( Prevoo et . al 1995 ) at screening  as 
part of eligibility and inclusion . DAS28  is calculated from 4 components: tender joint count 
(TJC), swollen joint count ( SJC), visual analogue scale (VAS) of the subject‚Äôs global health, 
and the laboratory parameter erythrocyte sedimentation rate (ESR) , such that: 
ùê∑ùê∑ùê∑ùê∑ùê∑ùê∑ 28= 0. 56ÔøΩùëáùëáùëáùëáùëáùëá + 0. 28ÔøΩùê∑ùê∑ùëáùëáùëáùëá + 0.7 ln(ùê∏ùê∏ùê∑ùê∑ùê∏ùê∏) + 0. 014(ùëâùëâùê∑ùê∑ùê∑ùê∑) 
A DAS28 score of higher than 5.1 is indi cative of high disease activity  whereas a DAS28 
below 3.2 indicates low disease activity. A subject with a  DAS28 lower than 2.6 is considered 
to be  in remission . For consistent scoring, the following calculator should be utilized: 
https://qxmd.com/calculate/ .  See Appendix 3 for details.  
8.3.3  Other  
8.3.3.1  28-joint Count (SJC and TJC)  
The 28- joint count will be performed for swollen and/or tender joints in the following: 
shoulder, elbow, wrist, MCP and PIP, and knee. Joint swelling is defined as soft tissue swelling 
that is detectable along the joint margins. Joint tenderness is defined as the presence of pain in 
a joint at rest with pressure or on movement of the joint  [57]. This assessment will be  used as 
an input parameter for 2010 ACR/EULAR score and DAS28 score. 
8.3.3.2  Patient Assessment of Pain (VAS)  
Patient assessment of pain will be evaluated using the visual analog scale (VAS). Using a ruler, 
the score will be determined by measuring the distance (mm) on the 10- cm line between the 
‚Äòno pain‚Äô anchor and the patient‚Äôs mark, providing a range of scores from 0 to 100. This 
assessment will be  used as an input parameter for DAS28 score. 
8.3.3.3  Acute -phase Reactant  
ESR and CRP will be obtained in the RA- specific laboratory panel (see Table 7).  This 
assessment will be used as an input parameter for 2010 ACR/EULAR score and DAS28 
score.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 46 of 74 
 8.4 Imaging 
8.4.1  Image Acquisit ion 
8.4.1.1  Planar Scintigraphy  
Bilateral hand and wrist p lanar image acquisition occurs in Arm 1 and 2 subjects beginning 
60-75 minutes following Tc 99m tilmanocept injection . Refer to the NAV3 -35 Image 
Acquisition Guidelines for all required imaging technical specifications and acquisitions.  
8.4.1.2  SPECT/CT  
SPECT/CT is performed for Arm 2 subjects on the bilateral hands and wrists only following 
the planar scan . Refer to the NAV3 -35 Image Acquisition Guidelines for all required imaging 
technical specifications and acqui sitions.  SUV will be calculated for DAS28 joints of interest 
according to standard methods. See the NAV3- 35 Image Review Charter and Statistical 
Analysis Plan for more details.  
8.4.2  Tilmanocept Uptake Value ( TUV) 
TUV is a quantitative imaging metric used to cha racterize the amount of CD206 activity on 
planar imaging. Results from prior Phase 1 and 2 studies  have demonstrated that TUV is a 
sensitive and specific predictor of visually interrogated Tc  99m tilmanocept localization in 
joint regions with presumed inflammatory macrophage activity. A per -joint TUV (TUV joint) 
relative ratio will be calculated for the each of the 22 DAS -28 joints located in the hands and 
wrists. A subject -level global TUV (TUV global) assessed across the 22 joints will be used as an 
indicat ion of overall disease burden.  
For all subjects, delegated trained imaging scientists blinded to all clinical subject information 
will perform semi- automated ROI drawing on planar images of the bilateral hands and wrists 
to derive relevant count statistic s, which are input parameters for TUV joint and TUV global. TUV 
metrics are further described in the NAV3 -35 Statistical Analysis Plan.  
8.5 Adverse Events 
8.5.1  Definition of Adverse Event  
The definitions below follow International Conference on Harmonization (ICH) ‚Äì Good Clinical Practice (GCP) (see also ICH Guideline for Clinical Safety Data Management:  Definitions and Standards for Expedited Reporting). 
An AE is defined as any untoward medical occurrence in a subject administered a 
pharmaceuti cal product and which does not necessarily have a causal relationship with this 
treatment.  An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal 
(investigational) product.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 47 of 74 
 Any clinically significant change in a condition (worsening) from screening that results in a 
change in subject management will be considered  an AE and will be recorded on the AE page 
of the CRF. 
By definition for this study, all untoward medical occurrences beginning on the Visit 2 (Day 
0) until the final visit (variable per arm)  are to be reported as AEs.  AEs continuing after study 
completio n will be followed to normalization or stabilization. Additionally, untoward medical 
events occurring prior to the day of Tc 99m tilmanocept administration will be collect ed and 
added to the subject‚Äôs medical history unless they are related to a study proc edure, in which 
case the event will be recorded as an AE . SAEs will be reported from the time of consent 
through the end of participation. 
8.5.2  Categories for Adverse Event Assessment  
The severity of an AE is classified according to the following categories, taking into account 
the possible range of the intensity of the event: 
‚Ä¢ Mild   The adverse event is transient and easily tolerated by the subject.  
‚Ä¢ Moderate   The adverse event causes the subject discomfort and interrupts the 
subject‚Äôs usual activities  
‚Ä¢ Severe  T he adverse event causes considerable interference with the subject‚Äôs 
usual activities and may be incapacitating or life -threatening. 
 Specific drug treatment  
Any specific drug treatment will be documented.  
Causal relationship to investigational product The investigator will use the following definitions to assess the relationship of the adverse 
event to the use of investigational product:  Definitely related:  Event can be fully explained by administration of the 
investigational product. 
Probably related:  Event is most likely to be explained by administration of the investigational product rather than the subject‚Äôs clinical state or other agents/therapies.  
Possibly related:  Event may be explained by administration of the investigational product or by the subject‚Äôs clinical state or other agents/therapies.  
Probably not related: Event is most likely to be explained by the subject‚Äôs clinical state or other agents/therapies, rather than the investigational product. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 48 of 74 
 Definitely not related:  Event can be fully explained by the subject‚Äôs clinical state or other 
agents/therapies.  
For causality assessments, events meeting the categories of definitely, probably, or possibly related will be considered to be related to investigational product. 
Causal relationship to study procedure  
The investigator will use the following definitions to assess the relationship of the adverse 
event to  study procedure :  
Definitely related:  Event can be fully explained by the study procedure. 
Probably related:  Event is most likely to be explained by the study rather than the subject‚Äôs clinical state or other agents/therapies.  
Possibly related:  Event may be explained by the study procedure or by the subject‚Äôs clinical state or other agents/therapies.  
Probably not related: Event is most likely to be explained by the subject‚Äôs clinical state 
or other agents/therapies, rather than the study procedure. 
Definitely not related:  Event can be fully explained by the subject‚Äôs clinical state or other agents/therapies.  
For causality ass essments, events meeting the categories of definitely, probably, or possibly 
related will be considered to be related to study.  
8.5.3  Assessments and Documentation of Adverse Events  
Attention shall be paid to the occurrence of AEs for the duration of subject participation. Events occurring prior to Visit 2 ( Day 0 ) will be recorded in the subject‚Äôs medical history  unless 
related to study procedure, in which case the event will be recorded as an AE . Untoward 
medical events beginning on Visit 2 ( Day 0 ) until the final visit (variable per arm)  will be 
reported as adverse events.     
Any AE (observed, volunteered, or elicited) should be recorded in detail in the source 
documentation. 
The following information is required: 
‚Ä¢ The date  and time of onset of any AE. 
‚Ä¢ The duration (the entire duration of an event or symptom, calculated from date of onset 
to date of end, if not recorded directly). 
‚Ä¢ The seriousness of the AE will be assessed by the investigator.  If the investigator deems that an AE qualifies as an SAE, a special form provided by the sponsor should be completed and the event must be immediately reported to the sponsor.  A definition of serious adverse events is provided in Section 8.5.5. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 49 of 74 
 ‚Ä¢ The maximum intensity (mild, moderate, or severe). 
‚Ä¢ Whether drug treatment was administered for the event, any specific drug treatment 
must be documented. 
‚Ä¢ The relationship of the AE to the investigational product and to study conduct (for 
definitions, see above). 
‚Ä¢ The outcome  of the AE (resolved, resolved with sequelae, not resolved, unknown, 
death).  
 AEs will be coded according to an internationally recognized dictionary (Medical Dictionary for Regulatory Activities [MedDRA]).  
8.5.4  Expected Adverse Events  
Investigational Product- Related Risks  
In all completed studies of Lymphoseek  (Tc 99m tilmanocept) , involving 553 subjects, only 3 
events (breast pain and injection site pain reported by subjects with breast cancer and injection site irritation reported by a subject with head and neck squamous cell cancer) were deemed definitely related to the administration of Lymphoseek by the investigator. The most common adverse reactions (incident <  1%) have been 
lack of effect (<  0.067%), injection site pain (<  
0.02%) and rash (<  0.02%) . Adverse events from the radioactive dose are not expected, since 
the applied radiation doses are far below doses that can cause acute effects in human tissues. Routes of administration included: subcutaneous, intradermal, and peritumoral. 
In addition to the Lymphoseek pre -approval clinical studies, post -marketing surveillance 
shows that Lymphoseek has been administered to more than 450,000 patients with not a single 
drug- related SAE. Routes of administration included: subcutaneous, intradermal, and 
peritu moral.  
The intended route of administration in this study is intravenous. There have been 
approximately 280 IV administrations of Tc 99m tilmanocept to date , and no SAEs or AEs 
related to the product have been reported to date.  
Risks of Imaging Procedures 
Radiation dose considerations from Tc 99m Tilmanocept planar and SPEC/CT scans  ‚Äì Patients 
enrolled in this trial will have hand/wrist planar gamma camera scans following Tc 99m 
Tilmanocept injection, with subjects enrolled in Arm 2 also receiving one hand/wrist SPECT/CT scan.   
The average effective radiation dose per 10 mCi Tc 99m Tilmanocept injection is calculated 
to be 2.7 mSv (equivalent to about ten months of natural background radiation received in the US). Subjects enrolled in Arm 1 will receive o ne injection, equal to 2.7 mSv total; subjects 
enrolled in Arm 2 will receive one injection plus one SPECT/CT scan- with an estimated 
effective dose of 1 mSv for the CT portion- amounting to 3.7 mSv total. T herefore, t he 
maximum possible dose of ~ 3.7 mSv for any enrolled subject (no one will cross over into more 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 50 of 74 
 than one study arm) is considered to be a minor to intermediate  risk level corresponding to the 
benefit to the patient [ category II b based on the International Commission on Radiological 
Protection 62 (ICRP62) ] and is balanced against the possible substantial societal benefit that 
can be gained from the trial (European Commission Radiation Protection 99, 1998 and ICRP 
62, 1992). For further reference, the effective dose from a standard CT abdomen and pelvis, with and without contrast, is up to 20 mSv.  
Precautionary Measures  
Special precautionary measures are not considered necessary for this study.  In case of 
emergency, standard emergency procedures will be employed. 
Unexpected Adverse Events  
An unexpected adverse event is defined as an adverse reaction that in nature and severity is 
not consistent with the applicable product information (e.g., Investigator‚Äôs Brochure).  Any adverse experience that is not listed in the current Investigator‚Äôs Br ochure or which is, with 
regard to the specificity or severity, not consistent with the risk information shall be regarded as unexpected.   
Examples would be (a) acute renal failure listed in the Investigator‚Äôs Brochure with a subsequent new report of inter stitial nephritis and (b) hepatitis with a first report of fulminant 
hepatitis.  ‚ÄúUnexpected‚Äù as used in this definition refers to an adverse drug experience that has not been previously observed and included in the Investigator‚Äôs Brochure, rather than from the perspective of such experience not being anticipated from the pharmacological properties of the investigational product. 
8.5.5  Serious Adverse Events  
Definition of Serious Adverse Events  
The following SAE definition is based on ICH guidelines and the final  rule issued by the Food 
and Drug Administration (FDA) and effective 06 Apr 1998.   
An SAE is classified as any untoward medical occurrence that at any dose: 
‚Ä¢ results in death, or 
‚Ä¢ is life threatening, or 
‚Ä¢ requires inpatient hospitalization or prolongation of existing hospitalization, or 
‚Ä¢ results in persistent or significant disability/incapacity, or  
‚Ä¢ is a congenital anomaly/birth defect, or 
‚Ä¢ is an important medical event (see paragraphs below).  
 
The term ‚Äòlife threatening‚Äô in the definition refers  to an event in which the subject was at risk 
of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 51 of 74 
 Medical and scientific judgment should be exercised in deciding whether it is  appropriate to 
report an AE as serious also in other situations, such as important medical events that may not 
be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definition above.  These should also usually be considered serious.  Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm or blood dyscrasias or convulsions that do not result in subject hospitalization.  
Actions and reporting obligations in case of serious adverse events 
The investigator should take appropriate diagnostic and therapeutic measures to minimize the 
risk to the subject.   
If any SAE occurs over the course of the study, investigators or other site personnel will inform 
Navidea Biopharmaceutical representatives within 1 day (i.e., within 24 hours) of becoming 
aware of the SAE. Written notification of the SAE will be emailed  to Navidea 
Biopharmaceuticals Pharmacovigilance at  safety@navidea.com . For fatal or life -threatening 
adverse events where important or relevant information is missing, active follow -up is 
undertaken immediately. 
Pregnancy will have the same time reporting obligations to the sponsor as SAEs. Upon 
notification, Navidea will provide a form for collection of pregnancy information. 
All SAEs must also be recorded on the Adverse Event eCRFs. Notification of the IRB(s) The sponsor and/or the investigator will notify the IRB(s) about all relevant events (e.g., 
serious adverse events [SAEs] and Suspected, Unexpected, Serious Adverse Reactions 
[SUSARs]) according to all applicable regulations. 
Notification of the authorities  
The sponsor will process and report all relevant events (e.g., SAEs, SUSARs) to the authorities 
according to all applicable regulations. 
Sponsor‚Äôs notification of the investigators The sponsor will inform all investigators about reported relevant events (e.g., SAEs, SUSARs) 
according to all applicable regulations. 
8.6 Physical Examination 
Complete physical examinations will be conducted at screening  including height and weight 
assessments. A physical exam that has been  conducted as standard of care prior to signing 
informed consent may be used if it was  performed within 30 days of injection. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 52 of 74 
 Physical examinations will be performed for the following body systems: 
‚Ä¢ General Appearance  
‚Ä¢ Skin/dermatological 
‚Ä¢ Eyes, ears, nose, throat 
‚Ä¢ Head and neck (including thyroid) 
‚Ä¢ Lungs 
‚Ä¢ Heart  
‚Ä¢ Abdomen (liver, kidney, spleen, gastrointestinal) 
‚Ä¢ Lymph nodes 
‚Ä¢ Musculoskeletal  
‚Ä¢ Nervous system 
 
8.7 Vital Signs 
Vital signs comprise the measurement of body temperature, heart rate, respiration, systolic and 
diastolic blood pressure. All measurements will be taken after the subject has been in a resting position for at lea st 1 minute. Vital signs will be measured at screening, within 30 minutes 
before investigational product injection, and within 30 minutes post injection. Any clinically 
significant change from screening (worsening) that results in a change in subject management will be considered an AE and will be recorded on the AE page of the CRF. 
8.8 Clinical Laboratory Parameters  
Table  7  Clinical Laboratory Parameters  
Hematology Hemoglobin (Hgb), hematocrit (HCT), platelets, neutrophils , 
basophils, lymphocytes, monocytes, red blood cells (RBC), white blood cells (WBC) 
Serum chemistry   Aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase, total bilirubin, creatinine, chloride, potassium, sodium, total protein, albumin, carbon dioxide (CO
2)/bicarbonate, blood urea nitrogen (BUN), glucose  
Urinalysis  pH, specific gravity  
Rheumatoid Panel  Erythrocyte sedimentation rate (ESR), C -reactive protein (CRP), 
rheumatoid f actor (RF); anti-c itrullinated peptide antibody 
(ACPA)  
 
All laboratory reports must be promptly reviewed for clinical significance by the investigator, 
and upon review, initialed and dated by the investigator. 
Good clinical practice would suggest that a copy of the laboratory results also be provided to 
the subject‚Äôs referring physician. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 53 of 74 
 Only abnormal laboratory values that are evaluated as being clinically significant will be 
collected in the electronic database. Any change in a laboratory value, which results in a change in subject management (additional controls or treatment required), will be reported as a clinically significant change. Clinically significant changes in laboratory parameters, which are not the result of laboratory error, are to be recorded as AEs.  
Any clinically significant changes in laboratory values are to be followed up with repeated tests at appropriate intervals (as determined by the investigator) until the values return to baseline level or until the abnormality is explained by the investiga tor. The expected amount 
of blood to be drawn is shown in Table 8. 
Table  8  Approximate Amount of Blood Drawn  
Timepoint  Test (Sample Volume)  Total Blood Drawn at Timepoint  
Visit 1 (Day -30 to -1) Chemistry (5 mL)  
Hematology (4 mL) 
RA panel (4 mL)  13 mL (2.6 teaspoons)  
Visit 2 (Day 0) Chemistry (5 mL)  
Hematology (4 mL) 9 mL (1.8 teaspoons)  
Total  22 mL  (~4.5 teaspoons)  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 54 of 74 
 9 STATISTICAL  METHODS  
This is a prospective, open- label, multicenter study of the patterns of variation in planar 
imaging using IV injected  Tc 99m tilmanocept for the quantitative detection of disease activity  
in the  skeletal joints of HC  subjects and subjects with  active RA. In addition to quantitative 
assessments, this study will also include qualitative (i.e., visual) evaluations of SPECT/CT in  
detecting localization within synovial spaces of the bilateral hands and wrists.   
The study is stratified into 2 groups. Arm 1 consists of HC subjects. Arm  2 consists of  HC 
subjects  and RA subjects  on stable therapy. 
9.1 Randomization Methods 
This study is not randomized.  
9.2 Safety Variables  
The safety analysis variables are defined as follows:  
‚Ä¢ Adverse events (AEs) 
‚Ä¢ Clinical laboratory tests (hematology, serum chemistry, urinalysis, and RA  panel)  
‚Ä¢ Vital signs 
 
9.3 Efficacy Variables 
The efficacy variables for this study are defined below:  
‚Ä¢ Quantitative determination of TUV joint and TUV global  
‚Ä¢ Qualitative (i.e., visual) dete rmination of tilmanocept localization in planar and 
SPECT/CT images of the bilateral hands and wrists; 
‚Ä¢ Quantitative determination of tilmanocept localization in planar and SPECT/CT 
images of the bilateral hands and wrists. 
 It is presumed that the presence of radiotracer uptake for a joint indicates the presence of 
activated macrophages. The use of the term ‚Äúlocalization‚Äù is synonymous with radiotracer uptake. 
The efficacy endpoints for this study, by arm, are as follows: 
Primary Endpoint(s) 
ARM 1  
‚Ä¢ The normal limits of TUV joint (on a per joint basis) in HC subjects, which are defined 
as the 5 and 95 percentiles of TUV joint of bilateral  joints (i.e., bilateral wrists, 
metacarpophalangeal joint [MCPs], p roximal interphalangeal [PIPs]). The normal 
range will be determined separately for each of the three blinded readers.  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 55 of 74 
 ARM 2  
‚Ä¢ The qualitative evaluations of SPECT/CT in detecting localization within synovial 
spaces of the bilateral hands and wrists in HCs and RA subjects. 
 
Secondary Endpoints 
ARM 1  
‚Ä¢ Applicab ility of the Normal (Gaussian) distribution to TUV joint data.  
 
 ARM 2  
 
‚Ä¢ Quantitative evaluations of Tc 99m tilmanocept localization from SPECT/CT within synovial spaces of the bilateral hands and wrists in HCs and RA subjects. 
‚Ä¢ Normative joint- specific SUV.  
 
‚Ä¢ Predictive value of planar scans for SPECT/CT scans.  
9.4 Sample Size Justification  
The study will enroll up to 135 evaluable subjects in Arms  1 and  2 allocated below, imaged at 
up to 8 study centers. Arm  1 will have N = 120 evaluable HC subjects, Arm 2 will have N = 
15 (5 HCs and 10 RA)  evaluable subjects.  A subject is considered evaluable if he/she meets 
the criteria for t he analysis population and has the data necessary for computing the primary 
endpoint.  
The sample size for Arm  1 was determined to provide acceptable precision for the  estimated 5 
and 95 percentiles. These percentiles will  be estimated with 95% nonparametric confidence intervals. Although the standard error formula for quantile estimators is known and quantile 
estimators obey a central limit theorem, relying  on the asymptotic Normal distribution seems imprudent. 
The sample will be stratified 3:1, females:males to reflect RA incidence in the United States 
[58, 59]. The sex -specific samples will be further stratified by age to reflect the Census 
estimated US population in 2019 (U.S. Census Bureau, 2020 [60]). The target sample sizes are 
given below.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 56 of 74 
 Age Range  Male  Female  Total  
30 to 39 years  8 23 31 
40 to 49 years  7 21 28 
50 to 59 years  8 22 30 
60 to 69 years  7 21 28 
70 years  and oldera 6 21 27 
Total  36 108 144 
a An effort will be made to target enrollment in this group to include 2 men and 8 women 80 years old and over .  
The existing data for HC subjects was used in a bootstrap procedure to evaluate the width of 
95% confidence intervals for the 95 percentiles for various sample sizes. The sponsor has decided for its business purposes that knowing the percentile to within 0.05 of its true value is sufficient. A sample of size N = 144 HC results  (this includes the subjects from Arm 1 of 
NAV3 -31) in 95% confidence intervals with half-widths less than 0.05. 
The sample size fo r Arm  2 was determined to be sufficient for the business purposes of the 
sponsor. The sample si ze for Arm 2 will be 5 HCs and 10 RA subjects.  
9.5 Statistical Analyses 
9.5.1  Analysis Populations  
The following populations are defined for this study: 
Intent -to-Diagnos e (ITD) Population  ‚Äì the ITD population includes all subjects who have 
been enrolled in the study, injected with Tc 99m tilmanocept, and received all imaging and 
evaluations necessary for the primary endpoint(s) appropriate to their respective arm . 
Per-Protocol (PP) Population  ‚Äì the PP population consists of all ITD subjects without major 
protocol violations. 
Safety Population  ‚Äì The safety population includes all subjects who have been enrolled in the 
study and injected with Tc 99m tilmanocept. 
9.5.2  Analysis of Baseline and Demographic Characteristics  
Baseline and demographic characteristics of the safety population will be summarized by 
subject status and overall.  Continuous variables (age, height, and weight ) will be summarized 
via mean, standard deviation, minimum, maximum, and number of non- missing responses. 
Categorical variables (gender, race and ethnicity) will be summarized via counts and percentages.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 57 of 74 
 9.5.3  Analysis of Efficacy Variables  
All efficacy analyses will be conducted on both the ITD and PP populations . The ITD 
population will be the primary analysis set. 
9.5.3.1  Primary Endpoint Arm 1  
The distribution of TUV joint in HC subjects will be summarized with descriptive statistics: 
mean, standard deviation, n, minimum, maximum, and median per reader, joint, and view. The 
5 and 95 percentiles will be estimated with quantile regression fitting an intercept as a fixed term.  The lower and upper limits of normal TUV
joint will be determined using non- parametric 
confidence intervals and kernel density- based confidence intervals . 
9.5.3.2  Primary Endpoint Arm 2  
Localization of tilmanocept in the hands and wrists will be summarized with frequency counts 
and percentages by reader and joint. 
9.5.3.3  Secondary Endpoint Arm 1  
Normal quantile plots will be provided per joint and reader, along with the p- value for the 
Shapiro- Wilk test of Normality.  
9.5.3.4  Secondary Endpoint s Arm 2  
SUV will be calculated and summarized on both a per -joint and a total of all joints with 
summary statistics: mean, standard deviation, n, minimum, maximum, and median. 
The predictive value of planar scans for SPECT/CT qualitative findings will be summarized 
per joint and reader with a crosstabulation and the uncertainty coefficients for row | column, 
column | row, and symmetric. The planar result will be deemed ‚Äú positive‚Äù (i.e., inflamed)  if 
TUV joint > 95 percentile of the reader resu lts for the same joint in Arm 1. Otherwise, the planar 
result will be deemed ‚Äúnegative‚Äù.  
Additional efficacy analyses may be described in the NAV3 -35 Statistical Analysis Plan 
(SAP).   
9.5.4  Analysis of Safety Variables  
All safety analyses will be conducted on the safety population. 
All AEs will be observed for each subject from the time of signing of informed consent until 
study completion. A treatment -emergent AE (TEAE) is defined as an AE whose start date is 
on or after the initial procedure date. If the proce dure date or the AE start date is missing, the 
AE will be considered treatment emergent.  
Prior to analysis all AEs will be coded using the MedDRA coding dictionary. Based on the coded terms, TEAEs will summarized by cohort and overall as follows: 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 58 of 74 
 ‚Ä¢ By system organ class (SOC) and preferred term (PT);  
‚Ä¢ By SOC and PT and relation to the study drug; 
‚Ä¢ By SOC and PT and severity. 
 
Observed and change from baseline vital sign parameters and hematology, clinical chemistry and urinalysis parameters will be summarized using descriptive statistics (mean, standard deviation, median, and range) for each Arm and overall at each time point.  
Other safety analyses may be described in the SAP for the study. 
9.5.5  Handling of Missing Values  
The analysis of the efficacy variables will be carried out on the observed data, i.e. a complete 
case analysis.  
9.5.6  Interim Analyses  
No interim analys es will be performed for this study.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 59 of 74 
 10 DATA HANDLING AND QUALITY ASSURANCE  
10.1 Data Recording 
Data required according to this protocol is captured in the subject‚Äôs source documentation and 
are to be entered onto the electronic CRFs (provided by the sponsor) as soon as possible. 
10.1.1  CRF Design  
Electronic CRFs (eCRFs) will be used for collecting all data gene rated during the trial. CRF 
completion details will be documented in a separate document that will be provided by the sponsor 
and maintained in the TMF.  
10.2 Monitoring 
This study will be monitored regularly by a clinical research associate (CRA) from the spons or 
or a contract research organization (CRO).  Monitoring procedures include 1 or more visits 
designed to clarify all prerequisites before the study starts.  Interim monitoring visits will take 
place on a regular basis according to a schedule fixed by mutual agreement.  During these visits, the CRA will check for completion of the entries on the CRFs, their compliance with the protocol and with GCP, and will compare the CRF entries with the source data. 
All data recorded in the CRF will be captured in the s ource documentation. 
The CRA will verify the correct use of the investigational product.  The investigational product 
will not be supplied to the investigator site prior to a favorable opinion from the IRB and the regulatory authority and, if appropriate, from the radiation protection authorities.  In addition, 
the CRA will determine whether all AEs or SAEs have been appropriately reported (including adherence to the time periods required for SAEs).   
10.3 Data Processing 
Study data documentation will be maintained specifying all relevant aspects of data processing for the study (including data validation, cleaning, correcting, releasing).  This documentation will be stored in the TMF.  
For data coding (e.g., AEs, medication, medical/surgical history), internationa lly recognized 
and accepted dictionaries will be used.  These and the processes used for coding will be specified in the data management plan  
10.4 Auditing 
A member of the sponsor‚Äôs (or a designated CRO) quality assurance unit may arrange to visit the investigator in order to audit the performance of the study at the study site and the study documents originating there.  The auditor(s) will usually be accompanied by a CRA or the study team leader.  The investigator will be informed about the outcome of the audit. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 60 of 74 
 In addition, inspections by health authority representatives and IRB(s) are possible at any time.  
The investigator is to notify the sponsor of any such inspection immediately. 
10.5 Archiving 
Essential documents shall be archived safely and securely in such a way that ensures that they are readily available upon authorities‚Äô request.  Patient (hospital) files will be archived according to local regulations and in accordance with the maximum period of time permitted by the hospital, institution, or private practice.  Where the archiving procedures do not meet the minimum timelines required by the sponsor, alternative arrangements must be made to ensure the availability of the source documents for the required period. 
The investigator/institution notifies the spo nsor if the archival arrangements change 
(e.g., relocation or transfer of ownership). The investigator site file is not to be destroyed without the sponsor‚Äôs approval. The investigator‚Äôs contract will contain all regulations relevant for the study center.  
Imaging data will be archived by the central imaging core lab according to the NAV3-35 
WorldCare Project Plan (WorldCare Clinical, Boston, MA).  
10.6 Premature Termination of the Study 
10.6.1  Termination by the Sponsor  
The Sponsor may terminate the study at any time for any of the following reasons: 
1. Failure to enroll subjects  
2. Protocol violations 
3. Inaccurate or incomplete data  
4. Unsafe or unethical practices  
5. Questionable safety of the investigational product 
6. Suspected lack of efficacy of the investigational product 
7. Administrative decision  
 
10.6.2  Termination by the Investigator  
If the Investigator terminates the study prematurely, the Investigator must do the following: 
‚Ä¢ Return all unused investigational products and related study materials to the Sponsor. 
‚Ä¢ Provide the IRB(s) and the sponsor with a written statement describing why the study 
was terminated prematurely.  Prompt compliance with this requirement is essential so that the sponsor may comply with its regulatory obligations. 
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 61 of 74 
 10.6.3  Study as a Whole  
The sponsor retains the right to prematurely terminate the study as a whole at any time.   
At the discretion of the sponsor, the entire study may be canceled for medical reasons.  In 
addition, the sponsor retains the right to end the study at any time if the study cannot be carried out as agreed upon in the protocol. In case of early termination or suspension of the study, the principal investigator/sponsor will promptly inform the investigator/institutions, regulatory authorities, and IRB of the termination or suspension and the reason for that. 
10.6.4  Center  
At any time, the study may be terminated at an individual center if:  
‚Ä¢ The center cannot comply with the requirements of the protocol. 
‚Ä¢ It is not possible for the center to comply with GCP standards. 
 
10.6.5  Study Pa rticipant  
Individual subjects may be withdrawn from the study according to the criteria specified in 
Section 4.4. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 62 of 74 
 11 ETHICAL AND LEGAL ASPECTS  
11.1 Ethical and Legal Conduct of the Study 
The planning and conduct of this clinical study are subject to national laws. Only when all of 
the requirements of the appropriate regulatory authority have been fulfilled will the study begin. The study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the ICH -GCP Guidelines of 17 Jan 1997. At the 
discretion of the investigator, the entire study may be canceled for medical reasons. In addition, the sponsor retains the right to end the study for medical -scientific or GCP -relevant reasons. 
In case of premature termination the investigators, IRB(s) and Regulatory Authorities will be informed by the Study Manager.  As required by local law, current safety -relevant information 
will be provided to the IRB(s) and the regulatory authorities by the sponsor. The sponsor will also inform all investigators about relevant safety events according to the applicable regulations. 
11.2 Subject Information and Consent 
All relevant info rmation on the study will be summarized in the subject consent form and 
additionally as required by the investigator‚Äôs institution in an integrated subject information and consent sheet. A sample informed consent form (ICF) is provided as a document separa te 
to this protocol. 
Based on this subject ICF, the investigator will explain all relevant aspects of the study to each 
subject, before entry into the study (i.e., before examinations and procedures associated with selection for the study are performed).  
The investigator will also mention that written approval of the IRB has been obtained.  Each 
subject will have ample time and opportunity to ask questions and will be informed about the right to withdraw from the study at any time without any disadvantage and without having to provide reasons for this decision.  Following this informative discussion, the subject will be asked if he/she is willing to sign and personally date a statement of informed consent.  Only if the subject voluntarily agrees to sign the  ICF and has done so, may he/she enter the study.  
Additionally, the investigator or his/her designee will personally sign and date the form.  The subject will receive a duplicate of the signed and dated form.  
The investigator will record in the source documentation the consent process including the time and date of obtaining informed consent. In the event that informed consent is obtained on the date that baseline study procedures are performed, the study record or subject's clinical record must clearly s how that informed consent was obtained prior to these procedures.
  
The ICF and any other written information provided to subjects will be revised whenever important new information becomes available that may be relevant to the subject‚Äôs consent, or there i s an amendment to the protocol which necessitates a change to the content of the subject 
information and/or the written ICF. The investigator will inform the subject of changes in a timely manner and will ask the subject to confirm his/her participation in  the study by signing 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 63 of 74 
 the revised ICF. Any revised written ICF and written information must receive the IRB‚Äôs 
approval/favorable opinion in advance of use. 
11.3 Financing/Financial Disclosure 
Each investigator (including principal and/or any subinvestigators; as well as their spouses and dependent children) who is directly involved in the treatment or evaluation of research subjects has to provide a financial disclosure according to all applicable legal requirements. All relevant documentation will be filed in t he sponsor trial master file and the investigator site file, as 
appropriate. 
11.4 Publication Policy 
The sponsor will be responsible for determining when any trial results should be published.  The sponsor will work jointly with the investigator(s) to publish information in a timely manner.  The investigator(s) shall not submit any information gleaned under the direct support or sponsorship of the sponsor to journals or professional societies without the prior written approval of the sponsor.  A ‚Äúpublication‚Äù is meant to include any abstract, letter, manuscript or public announcement in any form or length that contains information gleaned under the direct support or sponsorship of the sponsor. 
11.5 Subject Injury  
In general, if a subject is  injured as a direct result of the investigational product but not due to 
medical negligence on the part of the principal investigator or study staff, the sponsor will pay for reasonable and necessary medical treatment for the injury, to the extent the exp enses are 
not covered by the subject‚Äôs medical insurance, a government program, or other responsible third party.  If laws or regulations of the locality in which the study is taking place require additional payment of expenses, the sponsor shall comply with such law or regulation.  Where applicable, the sponsor has taken specific national insurance. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 64 of 74 
 12 REFERENCES 
1. Lassere MN, Rappo J, Portek IJ, Sturgess A, Edmonds JP: How many life years are 
lost in patients with rheumatoid arthritis? Sec ular cause- specific and all -cause 
mortality in rheumatoid arthritis, and their predictors in a long -term Australian 
cohort study . Internal medicine journal 2013, 43(1):66-72. 
2. Uhlig T, Moe RH, Kvien TK: The burden of disease in rheumatoid arthritis . 
PharmacoEconomics 2014, 32(9):841-851. 
3. Michelsen B, Uhlig T, Sexton J, van der Heijde D, Hammer HB, Kristianslund EK, 
Wierod A, Bakland G, Rodevand E, Kroll F  et al : Health -related quality of life in 
patients with psoriatic and rheumatoid arthritis: data fr om the prospective 
multicentre NOR -DMARD study compared with Norwegian general population 
controls . Annals of the rheumatic diseases 2018, 77(9):1290-1294. 
4. Verstappen SM: Rheumatoid arthritis and work: The impact of rheumatoid 
arthritis on absenteeism and presenteeism . Best practice & research Clinical 
rheumatology 2015, 29(3):495 -511. 
5. Demoruelle MK, Deane KD: Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis . Current rheumatology reports 2012, 
14(5):472-480. 
6. Anderson JJ, Wells G, Verhoeven AC, Felson DT: Factors predicting response to 
treatment in rheumatoid arthritis: the importance of disease duration . Arthritis 
and rheumatism 2000, 43(1):22 -29. 
7. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS: Benefit of very 
early referral and very early therapy with disease-modifying anti- rheumatic 
drugs in patients with early rheumatoid arthritis . Rheumatology (Oxford, 
England) 2004, 43(7):906 -914. 
8. van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW, van der Helm -van Mil AH: Long- term impact of delay in assessment of patients 
with early arthritis . Arthritis and rheumatism 2010, 62(12):3537-3546. 
9. Cush JJ: Early rheumatoid arthritis -- is there a window of opportunity?  The 
Journal of rheumatology Supplement 2007, 80:1 -7. 
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum 
NS, Burmester GR, Bykerk VP, Cohen MD  et al : 2010 Rheumatoid arthritis 
classification criteria: an American Colle ge of Rheumatology/European League 
Against Rheumatism collaborative initiative . Arthritis and rheumatism 2010, 
62(9):2569-2581. 
11. Sakellariou G, Scire CA, Zambon A, Caporali R, Montecucco C: Performance of the 
2010 classification criteria for rheumatoid arthritis: a systematic literature review and a meta -analysis . PloS one 2013, 8(2):e56528. 
12. Meyer PW, Hodkinson B, Ally M, Musenge E, Wadee AA, Fickl H, Tikly M, 
Anderson R: Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis . Mediators of inflammation 2010, 2010:158514. 
13. Olszewski WL, Pazdur J, Kubasiewicz E, Zaleska M, Cooke CJ, Miller NE: Lymph draining from foot joints in rheumatoid arthritis provides insight into local 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 65 of 74 
 cytokine and chemokine production and transport to lymph nodes . Arthritis and 
rheumatism 2001, 44(3):541-549. 
14. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid 
arthritis . The New England journal of me dicine 2001, 344(12):907-916. 
15. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: 
Transgenic mice expressing human tumour necrosis factor: a predictive genetic 
model of arthritis . The EMBO journal 1991, 10(13):4025-4031. 
16. Leizer T, Cebon J, Layton JE, Hamilton JA: Cytokine regulation of colony-
stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM -CSF and G -CSF production by interleukin-1 and tumor 
necrosis factor. Blood 1990, 76(10):1 989-1996. 
17. Westra J, Doornbos-van der Meer B, de Boer P, van Leeuwen MA, van Rijswijk MH, 
Limburg PC: Strong inhibition of TNF -alpha production and inhibition of IL -8 
and COX -2 mRNA expression in monocyte-derived macrophages by RWJ 
67657, a p38 mitogen- activated protein kinase (MAPK) inhibitor . Arthritis 
research & therapy 2004, 6(4):R384-392. 
18. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry- Smith A, Burls A: 
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost- effectiveness . Health technology assessment (Winchester, 
England) 2006, 10(42):iii-iv, xi- xiii, 1 -229. 
19. Kalden JR: Emerging role of anti- tumor necrosis factor therapy in rheumatic 
diseases . Arthritis research 2002, 4 Suppl 2 :S34-40. 
20. Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis . Lancet (London, England) 
2010, 376(9746):1094-1108. 
21. Vivar N, Van Vollenhoven RF: Advances in the treatment of rheumatoid arthritis . 
F1000prime reports 2014, 6:31. 
22. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E: 
Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an ina dequate response to conventional 
disease -modifying antirheumatic drugs or to an anti- tumour necrosis factor 
agent: a meta -analysis . Annals of the rheumatic diseases 2011, 70(2):266-271. 
23. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, 
Dorner T, Emery P, Fleischmann R, Gibofsky A  et al : Updated consensus statement 
on biological agents for the treatment of rheumatic diseases, 2010. Annals of the rheumatic diseases 2011, 70 Suppl 1 :i2-36. 
24. Tran TN, Caspard H, Magrini F: Inc idence density of serious infection, 
opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature . 
Open access rheumatology : research and reviews 2013, 5:21-32. 
25. Hresko A, Lin J, Solomon DH: Medical Care Costs Associated with Rheumatoid 
Arthritis in the US: A Systematic Literature Review and Meta -analysis . Arthritis 
care & research 2018. 
26. Heidari P, Cross W, Crawford K: Do out- of-pocket costs affect medi cation 
adherence in adults with rheumatoid arthritis? A systematic review . Seminars in 
arthritis and rheumatism 2018. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 66 of 74 
 27. Ishikawa H, Ziff M: Electron microscopic observations of immunoreactive cells in 
the rheumatoid synovial membrane . Arthritis and rheum atism 1976, 19(1):1 -14. 
28. Firestein GS, Zvaifler NJ: How important are T cells in chronic rheumatoid 
synovitis? Arthritis and rheumatism 1990, 33(6):768-773. 
29. Kinne RW, Stuhlmuller B, Burmester GR: Cells of the synovium in rheumatoid arthritis. Macrop hages . Arthritis research & therapy 2007, 9(6):224. 
30. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh 
A, McInnes IB, Solomon DH, Strand V  et al : Rheumatoid arthritis . Nat Rev Dis 
Primers 2018, 4:18001. 
31. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP: Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment . Arthritis and 
rheumatism 2002, 46(8):2034-2038. 
32. Cutolo M, Sulli A, Barone A, Seriolo B, Accardo S: Macrophages, synovial tissue 
and rheumatoid arthritis . Clinical and experimental rheumatology 1993, 11(3):331-
339. 
33. Kennedy A, Fearon U, Veale DJ, Godson C: Macrophages in synovial 
inflammation . Fron tiers in immunology 2011, 2:52. 
34. Ma Y, Pope RM: The role of macrophages in rheumatoid arthritis . Current 
pharmaceutical design 2005, 11(5):569-580. 
35. Bresnihan B: Pathogenesis of joint damage in rheumatoid arthritis . The Journal of 
rheumatology 1999, 26(3):717 -719. 
36. Mulherin D, Fitzgerald O, Bresnihan B: Synovial tissue macrophage populations 
and articular damage in rheumatoid arthritis . Arthritis and rheumatism 1996, 
39(1):115-124. 
37. Yanni G, Whelan A, Feighery C, Bresnihan B: Synovial tissue macrophages and 
joint erosion in rheumatoid arthritis . Annals of the rheumatic diseases 1994, 
53(1):39 -44. 
38. Vieira -Sousa E, Gerlag DM, Tak PP: Synovial tissue response to treatment in 
rheumatoid arthritis . Open Rheumatol J 2011, 5 :115-122. 
39. Orr C, Vieira -Sousa E, Boyle DL, Buch MH, Buckley CD, Ca√±ete JD, Catrina AI, 
Choy EHS, Emery P, Fearon U  et al : Synovial tissue research: a state-of- the-art 
review . Nature Reviews Rheumatology 2017, 14:60. 
40. Baeten D, Houbiers J, Kruithof E, Vandooren B, Van den Bosch F, Boots AM, Veys 
EM, Miltenburg AM, De Keyser F: Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical tri als in rheumatoid 
arthritis . Annals of the rheumatic diseases 2006, 65(8):990-997. 
41. Filkova M, Cope A, Mant T, Galloway J: Is there a role of synovial biopsy in drug 
development?  BMC musculoskeletal disorders 2016, 17:172. 
42. Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, Fearon U, 
Fitzgerald O, Gerlag DM, Rooney T, van de Sande MG  et al : Synovial tissue 
sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers . J Rheumatol 2009, 36 (8):1800-
1802. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 67 of 74 
 43. Smith MD, Kraan MC, Slavotinek J, Au V, Weedon H, Parker A, Coleman M, 
Roberts-Thomson PJ, Ahern MJ: Treatment -induced remission in rheumatoid 
arthritis patients is characterized by a reduction in macrophage conten t of 
synovial biopsies . Rheumatology (Oxford, England) 2001, 40(4):367-374. 
44. Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, Tak PP: 
Absence of changes in the number of synovial sublining macrophages after 
ineffective treatment for rheum atoid arthritis: Implications for use of synovial 
sublining macrophages as a biomarker . Arthritis and rheumatism 2007, 
56(11):3869-3871. 
45. van de Sande MG, de Hair MJ, Schuller Y, van de Sande GP, Wijbrandts CA, Dinant 
HJ, Gerlag DM, Tak PP: The features  of the synovium in early rheumatoid 
arthritis according to the 2010 ACR/EULAR classification criteria . PloS one 
2012, 7(5):e36668. 
46. Townsend MJ: Molecular and cellular heterogeneity in the Rheumatoid Arthritis 
synovium: clinical correlates of synovitis . Best practice & research Clinical 
rheumatology 2014, 28(4):539 -549. 
47. van de Sande MG, Baeten DL: Immunopathology of synovitis: from histology to 
molecular pathways . Rheumatology (Oxford, England) 2016, 55(4):599-606. 
48. Orr C, Vieira -Sousa E, Boyle DL, Buch MH, Buckley CD, Canete JD, Catrina AI, 
Choy EHS, Emery P, Fearon U  et al : Synovial tissue research: a state-of- the-art 
review . Nature reviews Rheumatology 2017, 13(8):463-475. 
49. Astorri E, Nerviani A, Bombardieri M, Pitzalis C: Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology. Current pharmaceutical design 2015, 21(17):2216-2224. 
50. Dennis G, Jr., Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, 
Haverty PM, Gilbert H, Lin WY, Diehl L  et al : Synovial phenotypes in rheumatoid 
arthritis correlate with response to biologic therapeutics . Arthritis Res Ther 2014, 
16(2):R90. 
51. Pitzalis C, Kelly S, Humby F: New learnings on the pathophysiology of RA from synovial biopsies . Current opinion in rheumatology 2013, 25(3):334-344. 
52. Mandelin AM, 2nd, Homan PJ, Shaffer AM, Cuda CM, Dominguez ST, Bacalao E, 
Carns M, Hinchcliff M, Lee J , Aren K  et al : Transcriptional Profiling of Synovial 
Macrophages Using Minimally Invasive Ultrasound- Guided Synovial Biopsies in 
Rheumatoid Arthritis . Arthritis & rheumatology (Hoboken, NJ) 2018, 70(6):841-
854. 
53. Donlin LT, Rao DA, Wei K, Slowikowski K, McGeachy MJ, Turner JD, Meednu N, 
Mizoguchi F, Gutierrez- Arcelus M, Lieb DJ  et al: High dimensional analyses of 
cells dissociated from cryopreserved synovial tissue. bioRxiv 2018. 
54. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, Vos 
K, Lems WF, Wolbink GJ, Sijpkens D  et al : The clinical response to infliximab in 
rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium . Annals of the rheumatic diseases 2008, 
67(8):1139-1144. 
55. RSNA: Quantitative Imaging Biomarkers Alliance. Available at: http://www.rsna.org/QIBA.aspx. Radiological Society of North America 2018. 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 68 of 74 
 56. Kinahan PE, Fletcher JW: Positron emission tomography-computed tomography 
standardized uptake values in clini cal practice and assessing response to 
therapy . Semin Ultrasound CT MR 2010, 31(6):496-505. 
57. Scott DL, Houssien DA: Joint assessment in rheumatoid arthritis . Br J Rheumatol 
1996, 35 Suppl 2 :14-18. 
58. van Vollenhoven RF: Sex differences in rheumatoid ar thritis: more than meets 
the eye. BMC medicine 2009, 7:12. 
59. Oliver JE, Silman AJ: Why are women predisposed to autoimmune rheumatic diseases?  Arthritis research & therapy 2009, 11(5):252. 
60. U.S. Census Bureau, Population Division (2020) Annual Estimat es of the 
Resident Population for Selected Age Groups by Sex for the United States: April 1, 2010 to July 1, 2019.  
 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 69 of 74 
 Appendix 1 Schedule of Events  
Evaluation  Visit 1  
Screening  
(Day -30 to - 1) Visit 2  
(Day 0)  Visit 3  
Telephone  
(Day 5 ¬± 3)  - 00:30  
to 
- 00:01  00:00  
Injection  
 00:01  
to 
00:30  60 - 7 5 min  After Imaging  
Informed consent  1, 2       
Entry criteria  1, 2       
Medical History, RA history, demography  1, 2       
Physical examination  1, 2       
Clinical laboratory evaluation: chemistry, 
hematology, urinalysis  1, 2     1, 2  
RA panel  1, 2       
Urine pregnancy test  (women of CBP only)  1, 2 1, 2      
2010 ACR/EULAR  1, 2       
DAS28  (RA subjects only)   2       
Vital signs  1,2 1, 2  1, 2    
Tc 99m tilmanocept administration    1, 2     
Planar scan of bilateral hands/wrists      1, 2   
SPECT/CT of bilateral hands/wrists      2   
Concomitant medications  1, 2 1, 2     1, 2 
AE monitoring  1, 2 1, 2 1, 2 1, 2 1, 2  1, 2 
1   Arm 1  
2   Arm 2  
1,2 Arms 1 and 2  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 70 of 74 
 Appendix 2 2010 ACR/EULAR Criteria 
 Score  
Target population (Who should be tested?): Patients who   
1) Have at least 1 joint with definite clinical synovitis (swelling)*   
2) With the synovitis not better explained by another disease‚Ä†   
Classification criteria for RA (score -based algorithm: add score of categories A -D;  
A score of ‚â• 6/10 is needed for classification of a patient as having definite RA)‚Ä°   
A. Joint involvement¬ß   
1 large joint  0 
2 ‚Äì 10 large joints  1 
1 ‚Äì 3 small joints (with or without involvement of large joints)  2 
4- 10 small joints (with or without involvement of large joints)  3 
> 10 joints (at least 1 small joint)**  5 
B. Serology (at least 1 test result is needed for classification)‚Ä°‚Ä°   
Negative RF and negative ACPA  0 
Low-positive RF or low-positive ACPA  2 
High -positive RF or high-positive ACPA  3 
C. Acute -phase reactants (at least 1 test result is needed for classification) ‚Ä°‚Ä°   
Normal CRP and normal ESR  0 
Abnormal CRP or abnormal ESR  1 
D. Duration of symptoms¬ß¬ß   
< 6 weeks  0 
‚â• 6 weeks  1 
* The criteria are aimed at classification of newly presenting patients. In addition, patients with erosive disease 
typical of rheumatoid arthritis (RA) with a history compatible with prior fulfillment o f the 2010 criteria should 
be classified as having RA. Patients with longstanding disease, including those whose disease is inactive (with or without treatment) who, based on retrospectively available data, have previously fulfilled the 2010 criteria shoul d 
be classified as having RA.  
‚Ä† Differential diagnoses vary among patients with different presentations, but may include conditions such as systemic lupus erythematosus, psoriatic arthritis, and gout. If it is unclear about the relevant differential diagn oses 
to consider, an expert rheumatologist should be consulted.  
‚Ä° Although patients with a score of < 6/10 are not classifiable as having RA, their status can be reassessed and the criteria might be fulfilled cumulatively over time.  
¬ß Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by imaging 
evidence of synovitis. Distal interphalangeal joints, first carpometacarpal joints, and first metatarsophalangeal 
joints are excluded from assessment. Categories of joint distribution are classified according to the location and number of involved joints, with placement into the highest category possible based on the pattern of joint involvement.  
‚ÄúLarge joints‚Äù refers to shoulders, elbows, hips, knees, and ankles.  
 ‚ÄúSmall joints‚Äù refers to the metacarpophalangeal joints, proximal interphalangeal joints, second through fifth 
metatarsophalangeal joints, thumb interphalangeal joints, and wrists.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 71 of 74 
 ** In this category, at least 1 of the involved joints must be a small joint; the other joints can include any 
combination of large and additional small joints, as well as other joints not specifically listed elsewhere (e.g., 
temporomandibular, acromioclavicular, sternoclavicular, etc.).  
‚Ä†‚Ä† Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) for the laboratory 
and assay; low -positive refers to IU values that are higher than the ULN but ‚â§ 3times the ULN for the laborator y 
and assay; high- positive refers to IU values that are > 3 times the ULN for the laboratory and assay. Where 
rheumatoid factor (RF) information is only available as positive or negative, a positive result should be scored as 
low-positive for RF. ACPA = anti- citrullinated protein antibody.  
‚Ä°‚Ä° Normal/abnormal is determined by local laboratory standards. CRP = C -reactive protein; ESR = erythrocyte 
sedimentation rate.  
¬ß¬ß Duration of symptoms refers to patient self -report of the duration of signs or symptoms of synovitis (e.g., pain, 
swelling, tenderness) of joints that are clinically involved at the time of assessment, regardless of treatment status.  
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of  
Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569- 2581.  
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 72 of 74 
 Appendix 3 DAS28 Scoring  
Courtesy of http://www.iche.edu/newsletter/DAS28.pdf  

Technetium Tc 99m tilmanocept 
Clinical Trial Protocol: NA V3-35 
Sponsor Signatures Navidea Biopharmaceuticals, Inc. 
17 March 2021 
Appendix 4 
Study Title: Development of a Normative Database for Rheumatoid Arthritis 
(RA) Imaging with Tc99m Tilmanocept. 
Study Number: NAV3-35 
Original Date: 17 March 2021 
This clinical study protocol was s bject o critical review and has been approved by the 
sponso,---;;;~~ con ;:::::iting and/or app~;ing this p: col: 
Signed: Date: W1 /Mr 2-1 
William Regan 
Chief Compliance Officer 
Navidea Biopharmaceuticals, Inc. 
Signed:~ 6._~ Date: 231\1l11.,yZot,j 
Michael Blue , MD, FACEP 
Senior Medical Director 
Navidea Biopharmaceuticals, Inc. 
Signed:~,{ IL\\olo~ 
Bonnie Abbruzzese, MS,C 
Senior Director, Clinical Research & Development 
Navidea Biopharmaceuticals, Inc. 
Signed :~~ 
Michael Rosol, PhD 
Chief Medical Officer 
Navidea Biopharmaceuticals, Inc. 
Confidential Page 73 of74 Date: 3 / 2-~ / 2,-0~ I I 
Date: 3/~3/.J__ ) 
Technetium Tc 99m tilmanocept   Navidea Biopharmaceuticals, Inc.  
Clinical Trial Protocol: NAV3 -35  17 March 2021  
   
 
Confidential  Page 74 of 74 
 Appendix 5 Investigator‚Äôs Signature 
Study  Title:  Development of a Normative Database for Rheumatoid Arthritis 
(RA) Imaging with Tc99m Tilmanocept  
Study  Number:  NAV3 -35 
Original  Date:  17 March  2021 
I have read the protocol described above. I agree to comply with all applicable regulations 
and to conduct the study as described in the protocol.  
 
 
Signed:   Date:    
 